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PRESENTACIÓN 
 
     La homeostasis del sistema inmune es un proceso crítico por el cual el cuerpo 
establece y sustenta la tolerancia celular. Esta función se logra equilibrando la 
activación celular, el crecimiento y la muerte. La hiperactivación de las células T 
conduce a la autoinmunidad y a enfermedades relacionadas como el lupus eritematoso 
sistémico.  
    Entre las funciones biológicas que se atribuyen a p21, se incluyen las siguientes: 
inhibición del ciclo celular, senescencia y envejecimiento, apoptosis, reprogramación de 
células madre pluripotentes inducidas (iPS), como así también la reparación y 
diferenciación del ADN 1,2. Las células T deficientes en p21 tienen una importante 
ventaja proliferativa en comparación con las células de tipo salvaje (wild-type WT), tras 
la estimulación prolongada con IL-2 3. La ausencia de p21 provoca una acumulación 
inusualmente alta de células de memoria CD4+, lo cual conduce a una pérdida de 
tolerancia a los antígenos nucleares 4. p21 sólo controla la proliferación de células T 
activadas y de memoria, lo que sugiere que p21 forma parte del mecanismo de 
homeostasis de las células T de memoria y contribuye al mantenimiento de tolerancia 5. 
En estudios previos llevados a cabo en nuestro laboratorio utilizando ratones 
C57BL/6/lpr y MRL/lpr que sobreexpresan p21 en células T, se identificó una 
disminución de la autorreactividad y linfadenopatía en C57BL/6/lpr, así como una 
reducción de la mortalidad en ratones MRL/lpr. Estos datos muestran evidencia directa 
de un papel de p21 en el control de autorreactividad de células T autoinmune, sin que 
las respuestas de células T normales resulte afectada 6. p21 actúa como un regulador 
negativo de la actividad de los macrófagos, con independencia de su función clásica 
como un inhibidor del ciclo celular 7. Recientemente, hemos mostrado que la p21 regula 
el equilibrio en las vías de NF-κB entre p65-p50 y p50-p50 para mediar la plasticidad de 
los macrófagos en la tolerancia LPS 8. Aunque estos estudios identifican p21 como 
regulador negativo de la inmunidad innata y adaptativa, el mecanismo por el cual p21 
afecta las respuestas de las células T continúa sin elucidar. 
Se realizaron estudios para describir el papel de p21 en la activación de células T, y se 
definieron los siguientes objetivos:  
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1. Describir el mecanismo por el cual p21 controla las células T CD4+   
efectoras/memoria (de tipo memoria) via la estimulación del TCR, 
2. Examinar los efectos de p21 sobre la producción de IFN-γ tras la estimulación 
repetida del TCR, 
3. Determinar si p21 influye en las células T de tipo memoria de una manera TCR-
independiente y precisar su papel en la producción de IFN-γ, 
4. Estudiar el papel de p21 en la producción de especies reactivas de oxígeno 
mitocondrial en células T de tipo memoria CD4+, y 
5. Analizar cómo p21 afecta la producción de IFN-γ en células T de ratón p21-/-/lpr 
En este trabajo demostramos que p21 afecta la vía de activación de células T 
efectoras / memoria (de tipo memoria) reestimuladas pero no de células T naïve. Este 
efecto de p21 es independiente de las propiedades reguladoras del ciclo celular que han 
sido descritas y publicadas anteriormente para p21. Posteriormente a la estimulación 
secundaria TCR-dependiente de células T preactivadas, se observó un aumento en los 
indicadores de la activación temprana de células T tales como p-AKT, p- PKCθ y p-p65 
en p21-/- en comparación con células T de tipo salvaje (wild type – WT T-cells). Además, 
la deficiencia de p21 llevó a un aumento de los niveles de CARMA1, BCL10 y TRAF6, 
que inducen la activación de NF-κB. Para demostrar si la falta de p21 aumenta la 
respuesta de las células T, por una vía TCR-independiente, se estimularon células T 
preactivadas con IL 12/IL-18. Se demostró que este tratamiento resultó en una mayor 
producción de IFN-γ en células T p21-/- en comparación con las células T WT (wild type). 
Esta característica de las células T p21-/- estimuladas con citoquinas se asoció a un 
aumento de los indicadores de activación, de igual modo que la restimulación TCR-
dependiente. Para confirmar que este efecto de p21 sobre la activación de células T 
prestimuladas, observadas en las células T p21-/-, no era consecuencia de un efecto de 
falta de p21 sobre la maduración de las células T y/o sobre la activación primaria, 
utilizamos tecnología siRNA para reducir la expresión de p21 tras la activación de 
células T primarias. Los niveles más bajos de p21 condujeron a un aumento de los 
elementos implicados en la vía de activación de las células T. 
Para establecer aún más el vínculo entre p21 y la activación de células T, 
sobreexpresamos p21 durante la activación secundaria. p21 se clonó en vectores YFP. 
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Después de la transfección, se observaron niveles disminuidos de p-p65, p-AKT, p- 
PKCθ, CARMA1 y TRAF6. 
En general, estos resultados indican que p21 es un regulador negativo de los 
elementos clave de activación en células T estimuladas repetidamente. Como estos 
elementos son comunes a la activación de células T que son TCR-dependientes y 
citoquina-dependientes, concluimos que p21 podría afectar a una vía compartida por los 
dos procesos de activación. La activación mitocondrial de ROS (especies reactivas de 
oxígeno) es una de tales vías mencionadas. Se encontró que la falta de p21 llevó a un 
aumento de la producción mitocondrial ROS, lo que a su vez provocó un aumento en los 
indicadores de activación vinculados a la falta de p21. Los inhibidores específicos de la 
producción de ROS mitocondrial inhibieron el aumento de estos efectos. 
En conclusión, nuestros datos muestran que la activación de células T prestimuladas, 
las cuales tienen un fenotipo de memoria, por estimulación secundaria TCR-
dependiente o TCR-independiente, depende de p21 para controlar su respuesta. La 
ausencia de p21 provoca una mayor producción de ROS mitocondrial, lo que da lugar a 
un aumento de los factores de activación de las células T y finalmente conduce a la 
activación de NF-κB o a la producción de IFN-γ. 
Los efectos de p21 sobre la activación de las células T también se estudiaron en el 
contexto de la autoinmunidad. Los ratones p21-/-/lpr  desarrollan una enfermedad 
autoinmune severa y mueren por esta causa. En este estudio, explicamos cómo la falta 
de p21 aumenta la autoinmunidad lpr, ya que la ausencia de p21 aumenta la actividad 
de las células T y la producción de IFN-γ. 
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   ABSTRACT 
    Hyperactivation of T cells leads to autoimmunity and related diseases such as 
systemic lupus erythematosus.  We previously identified the p21 protein as a regulator of 
autoimmune manifestations.  Although several later studies from our group and other 
laboratories addressed the p21 effect on T cells and autoimmunity, the mechanism by 
which p21 directs its autoimmunity-suppressing effect remains a matter of debate. 
    Here we show that p21 affects the activation pathway of restimulated effector/memory 
(memory-like) T cells but not of naïve T cells.  This p21 effect is independent of its 
reported cell cycle regulatory properties.  After secondary TCR-dependent stimulation of 
preactivated T cells, we observed an increase in early T cell activation indicators such as 
p-AKT, p-PKCθ and p-p65 in p21-/- compared to wild type (WT) T cells. In addition, p21 
deficiency led to increased levels of CARMA1, BCL10 and TRAF6, which induce NF-κB 
activation.  To test whether lack of p21 augments T cell responses in a TCR-
independent pathway, preactivated T cells were stimulated with IL-12 and IL-18. This 
treatment led to higher IFN-γ production and increased activation indicators by p21-/- 
compared to WT T cells.  
   Overall, these results indicate that p21 is a negative regulator of key activation 
elements in repeatedly stimulated T cells.  As these elements are common to TCR-
dependent and cytokine-dependent T cell activation, we reasoned that p21 might affect 
a pathway shared by the two activation processes.  Mitochondrial ROS (reactive oxygen 
species) activation is such a pathway.  We found that lack of p21 led to increased 
mitochondrial ROS production, which in turn caused an increase in the activation 
indicators linked to lack of p21.  Specific inhibitors of mitochondrial ROS production 
inhibited the increase in these effects. 
    In conclusion, our data show that activation of prestimulated T cells, by secondary 
TCR-dependent or -independent stimulation depends on p21 to control their response. 
p21 attenuates mitochondrial ROS production, which decreases T cell activation factors 
and ultimately NF-κB activation and IFN-γ production. 
   The effects of p21 on T cell activation were also studied in the context of 
autoimmunity.  p21-/-/lpr mice develop severe autoimmune disease and die.  In this 
study, we explain how lack of p21 enhances lpr autoimmunity, as absence of p21 
increases T cell activity and IFN-γ production. 
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INTRODUCTION 
 
Immune system 
The immune system is a set of host defense strategies comprised of several biological 
structures and processes that protect the organism against pathogens, toxic and/or 
allergenic substances.  To achieve correct function, an immune system must detect a 
wide variety of pathogens, and discriminate them from healthy self-tissue.  To perform 
these functions, the host uses innate and acquired mechanisms, which include both self 
and non-self recognition 9. 
Innate immunity 
Microorganisms or toxins that enter an organism, meet the cells and mechanisms of the 
innate immune system, which includes anatomical barriers (physical and chemical) and 
cellular responses.  The cells involved in this process are macrophages, mast cells, 
dendritic cells, neutrophils, natural killer (NK) cells, eosinophils, and NK T cells.  In 
addition to cellular defenses, innate immunity also has humoral elements such as LPS 
binding protein, C-reactive protein, complement proteins, and antimicrobial peptides 
such as defensins 10.  The opsonized pathogen is phagocytosed by neutrophils.  
Monocytes and macrophages are then recruited to the infection site, and persist at sites 
of chronic inflammation and infection.  Macrophages and dendritic cells ingest the 
microbe and present its antigens in complex with major histocompatibility complex 
(MHC) proteins.  They thus have important role in adaptive immunity as antigen-
presenting cells. 
Macrophages also have other functions, such as the clearance of lipoproteins, debris 
and dead cells. They are thus crucial for sustaining a balanced response to homeostatic 
or tissue-damaging signals, and inflammatory disease can occur when this balance is 
disturbed 11.  Activation of the TLR4 signaling pathway by lipopolysaccharide (LPS) 
recruits downstream signaling proteins and induces the generation of reactive oxygen 
species (ROS) and pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6 and 
28 	
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TNFα in macrophages 12.  The NF-κB signaling system, which is involved in the 
production of these cytokines, is a prominent regulator of innate immunity 13,14. 
 Adaptive immunity 
Adaptive immunity acts against microorganisms that evade or overcome the innate 
immune response.  Components of this system activate, proliferate and create 
mechanisms to eliminate the microbes.  This system allows the body to recognize and 
remember a specific antigen.  If this antigen enters the body again, a rapid, appropriate 
immune response can arise.  There are two major types of adaptive immune responses, 
humoral immunity, mediated by antibodies produced by B lymphocytes, and cell-
mediated immunity, mediated by T lymphocytes.  In cell-mediated immunity, cells are 
dealing with virus-infected cells as well as intracellular bacteria; macrophages, natural 
killer cells, and antigen-specific cytotoxic T lymphocytes will be activated.  Antigens are 
phagocytosed by antigen-presenting cells (APC) and after processing, they will be 
presented on the APC surface to T cells.  There are four main categories of T cells, 
cytotoxic T cells, helper T cells, suppressor T cells and memory T cells. 
In humoral immunity, B cells play a key role.  These cells present antigens to the T cells 
or produce antibodies.  Antibody has a binding site for specific antigen. The B cells that 
do not become plasma cells will become memory B cells (like T cells). 
T cells 
In adaptive immunity, T cells have an essential function.  This cells contain several 
subsets, such as effector, helper, cytotoxic, memory, suppressor (regulatory), natural 
killer, mucosal-associated invariant and gamma/delta cells 15,16.  All T cells originate from 
hematopoietic stem cells in the bone marrow. Common lymphoid precursor cells that 
migrate to the thymus are known as T cell precursors (or thymocytes) and do not 
express a T cell receptor (TCR). 
Positive and negative selection 
Positive selection "selects for" T cells that can interact with the major histocompatibility 
complex (MHC) and involves the production of a signal by double-positive precursors 
that express either MHC Class I- or II-limited (restricted) receptors.  The signal produced 
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by these thymocytes results in recombination-activating gene (RAG) repression, long-
term survival and movement into the medulla, as well as differentiation into mature 
T cells.  Positive selection takes a number of days.  Double-positive thymocytes 
(CD4+CD8+) move deep into the thymic cortex, where they are presented with self-
antigens expressed by thymic cortical epithelial cells.  Only those thymocytes that 
interact with MHC-I or MHC-II correctly (neither too strongly nor too weakly) will acquire 
a vital "survival signal".  The remainder (if they do not interact strongly enough, or if they 
bind too strongly) will be removed by "death by neglect" (no survival signal).  This 
process ensures that the selected T cells will have an affinity for MHC that can serve 
effective functions in the body. Most thymocytes will die during this process. 
A thymocyte's fate is determined during positive selection.  Double-positive cells 
(CD4+CD8+) that interact well with MHC class II or class I molecules will finally become 
CD4+ or CD8+ cells, respectively.  When a T cell becomes a CD4+ cell, expression of its 
CD8 cell surface receptors is downregulated.  If the cell does not lose its signal, it will 
continue downregulating CD8 and become a CD4+ single-positive cell 16.  If signal 
interruption occurs, CD8 downregulation is halted and switches to downregulating CD4 
molecules instead, finally becoming a CD8+ single-positive cell. Thymocytes that can 
cause autoimmunity are not removed by this process, but these cells will be eliminated 
by a negative selection process that takes place in the thymic medulla. 
Thymocytes that bind strongly to self-MHC peptides are removed by negative 
selection.  The cells that survive positive selection migrate towards the boundary of the 
cortex and medulla in the thymus.  In the medulla, they are presented with a self antigen 
found on the MHC of medullary thymic epithelial cells (mTEC) 17.  mTEC must be 
autoimmune regulator (AIRE)-positive to correctly express self antigens from all tissues 
of the body on their MHC class I peptides.  Some mTEC are phagocytosed by thymic 
dendritic cells, which allows for presentation of self antigens on MHC class II molecules 
(positively selected CD4+ cells must interact with MHC class II molecules, so APC, that 
bear MHC class II must be present for CD4+ T cell negative selection).  Thymocytes that 
interact too strongly with the self-antigen receive an apoptotic signal that leads to cell 
death.  Some of these cells are nonetheless selected to become Treg cells.  The 
remaining cells leave the thymus as mature naïve T cells.  This process is important in 
30 	
 
 30 
central tolerance to prevent the formation of self-reactive T cells, which induce 
autoimmune diseases in the host. 
Briefly, beta selection is the first checkpoint, which permits continued thymic 
development of T cells able to be an effective pre-TCR with a constant alpha chain and a 
functional beta chain.  Positive selection controls T cells with a rearranged TCRα locus 
that can recognize peptide-MHC complexes with appropriate affinity.  T cells that bind 
too strongly to self-antigens are eliminated by negative selection in the medulla.  These 
selection processes allow self-tolerance by the immune system.  Typical T cells that 
leave the thymus (through the corticomedullary junction) are self-restricted, self-tolerant, 
and single positive. 
T helper cells (CD4+) 
Helper (CD4+) T cells play a central role in immune protection.  They help B cells make 
antibodies, induce macrophages to develop enhanced microbicidal activity, recruit 
neutrophils, eosinophils, and basophils to sites of infection and inflammation and, 
through cytokine and chemokine production, coordinate the fully equipped immune 
responses.  There are different T helper populations, including Th1, Th2, Th17, induced 
regulatory T (iTreg), Th9 and T follicular-helper (Tfh) cells.  Unusual activation of Th1 
cells is seen in most organ-specific autoimmune diseases, and Th2 cells are responsible 
for allergic inflammatory diseases and asthma 18.  The differentiation of naïve T cells into 
specific helper lineages is promoted by different transcription factors.  For Th1 cells, 
STAT1 and STAT4 (signal transducer and activator of transcription 1 and 4) are both 
important as they receive signals from interferons (IFN) and IL-12, respectively.  STAT1 
and STAT4 can induce T-beta cells to promote interferon-γ (IFN-γ) production and 
repress IL-4 transcription.  For Th2 cells, STAT5 or STAT6 can initiate specification by 
induction of the GATA3 transcription factor.  STAT3 also contributes to Th2 
differentiation 19. 
T helper cell lineage 
Naïve CD4+ T cells differentiate into different functional subsets (Scheme 1).  IL-12 and 
IL-4 induce Th1 and Th2 differentiation, respectively.  They antagonize each other in 
differentiation, and also inhibit the differentiation of Th17 cells.  IL-12 potentiates the 
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production of IFN-γ, tumor necrosis factor (TNF) and lymphotoxin.  IL-4 potentiates 
production of IL-4, IL-5 and IL-13.  CD4+ T cell differentiation to effector cells that 
produce IL-17 and IL-17F is promoted by IL-23, which express high IL-23R levels 20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCHEME 1 |  Differentiation of naïve T cells into functionally distinct effector subsets.  Naïve T cells 
differentiate into distinct T helper cell subsets based on specific combinations of cytokine signals.  Each 
T helper cell subset is characterized by cytokine production, which has specific functions. 
T cell activation pathway 
Peptide-MHC (pMHC) binding to the TCR induces a cascade of intracellular events 
critical for T cell activation.  The TCR is able to trigger a diverse range of biological 
responses according to its affinity for the pMHC ligand it encounters; this is at the basis 
of self-nonself discrimination in both the thymus and the periphery.  The TCR signal 
transduction network is very sensitive.  The presence of a few foreign agonist pMHC 
ligands is sufficient to induce sustained Ca2+ influx and cytokine production 21. 
TCR activation induces several signaling cascades that finally determine cell fate by 
regulating cytokine production, cell survival, proliferation, and differentiation.  An early 
event in TCR activation is phosphorylation of immunoreceptor tyrosine-based activation 
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motifs (ITAM) on the cytosolic side of the TCR/CD3 complex by lymphocyte protein 
tyrosine kinase (Lck).  Zeta chain-associated protein kinase 70 (Zap70) is recruited to 
the TCR/CD3 complex, where it is activated and promotes recruitment and 
phosphorylation of downstream adaptor or scaffold proteins.  The SLP-76 adaptor 
protein is phosphorylated by Zap70 to recruit Vav (a guanine nucleotide exchange 
factor), the adaptor proteins NCK and GADS, and an inducible T cell kinase (Itk).  
Phosphorylation of phospholipase Cγ1 (PLCγ1) by Itk lead to hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to produce the second messengers 
diacylglycerol (DAG) and inositol trisphosphate (IP3).  DAG activates PKCθ and the 
MAPK/ERK (mitogen-activated protein kinase/extracellular regulated kinase) pathways, 
both of which promote transcription factor NF-κB activation.  IP3 triggers Ca2+ release 
from the endoplasmic reticulum (ER) to promote entry of extracellular Ca2+ into the cells 
via calcium release-activated Ca2+ (CRAC) channels.  Calcium-bound calmodulin 
(Ca2+/CaM) activates the phosphatase calcineurin, which promotes IL-2 gene 
transcription through the NFAT transcription factor (Scheme 2).  There is feedback 
regulation at several points in these pathways, which allows for different outcomes 
depending on cell type and environment.  Incorporation of signals from additional cell 
surface receptors (such as CD28 or LFA-1) gives further cellular response regulation 
22,23. 
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SCHEME 2 |  T cell receptor signaling pathway.  When a T cell receptor binds to a specific MHC-peptide 
complex, a number of events take place within the cell.  First, intracellular Src family tyrosine kinase 
enzymes such as fin are activated by CD45, which removes inhibitory phosphate groups from the enzymes.  
The activated fin kinase then phosphorylates the ITAM at the CD3 components.  Phosphorylated ITAMs are 
binding sites for a second kinase, ZAP70, which can bind to the phosphorylated ζ (zeta) chain.  The co-
receptor (here, CD4) is able to bind the same MHC-peptide complex as the TCR.  This binding brings the 
co-receptor associated tyrosine kinase LCK to ZAP70, which leads to LCK phosphorylation and thus 
activates ZAP70.  Activated ZAP-70 can now bind to and activate a number of intracellular signaling adaptor 
proteins such as LAT, which in turn are able to activate other signaling pathways within the cells. 
The phosphoinositide 3-kinase (PI3K) signaling pathway plays essential roles in T cell 
activation, and regulates various processes in the normal cell such as growth, 
proliferation, survival, motility, and metabolism 24.  Protein adaptors such as Gab2 or the 
IRS family are recruited by activated tyrosine kinase receptor (RTK), which bind to p85 
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(a regulatory PI3K subunit), which then activates p110α, β and δ (catalytic subunits of 
PI3K). The activated PI3K complex transforms PIP2 into PIP3.  Phosphatidylinositol 3 
phosphate (PIP3) recruits PDK1 and AKT to the plasma membrane, where PDK1 
phosphorylates AKT on Thr308.  AKT also is phosphorylated by PDK2 on Ser473 
(Scheme 3).  Fully activated AKT modulates several substrates important for cell 
survival, cell cycling and cell growth 25. 
 
 
 
 
 
 
 
 
 
 
SCHEME 3 |  PI3K/AKT signaling pathway.  PI3K signaling is initiated by growth factor binding to the 
tyrosine kinase receptor, which leads to receptor dimerization.  As a result, the lipid kinase PI3K is recruited 
to the internal docking site and is activated.  PI3K then converts membrane lipid PIP2 to the PIP3 form, 
which in turn triggers activation of the key signaling kinase AKT.  AKT promotes cell growth and reduces cell 
death. 
Regulation of IFN-γ  production in T cells 
IFN-γ has a key role in host defense.  T cells and natural killer (NK) cells are the major 
sources of this cytokine.  A combination of IL-12/IL-18 synergistically induces T cell 
IFN-γ production without TCR engagement.  This suggests that there are at least two 
activation pathways responsible for IFN-γ production by T cells, a TCR-dependent 
pathway and an IL-12/IL-18 TCR-independent pathway.  
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Engagement of the heterodimeric IL-12 receptor leads to STAT4 phosphorylation after 
recruitment of the Tyk2 and JAK2 kinases.  STAT4 promotes IFN-γ transcription.  After 
binding of IL-18 to its receptors, the MAPK pathway is activated downstream of the 
adapter MyD88.  This leads to stabilization of IFN-γ mRNA and enhances IFN-γ 
production 26.  The IL-12/IL-18 pathway activates p38 MAPK, which selectively increases 
Th1 responses (Scheme 4).  The synergy between IL-12 and IL-18 involves many 
transcription factors that bind to specific DNA sequences in the gene that encodes the 
IFN-γ promoter 27. 
 
 
 
 
 
 
 
 
 
 
 
SCHEME 4 |  Synergy between IL-12 and IL-18 for the induction of IFN-γ  production.  IL-12 receptor 
stimulation induces Jak2 and Tyk2 phosphorylation, which results in STAT4 activation and its translocation 
to the nucleus.  The IL-8 receptor signals through IRAK1 and TRAF6, and leads to NF-κB activation. 
 
T cell activation by IL-4 induces Th0 to Th2 development 
Interleukin-4 is a cytokine that regulates diverse biological functions, including 
proliferation, differentiation, and apoptosis in several cell types of hematopoietic and 
non-hematopoietic origin.  It has an important role in regulating Th0 cell differentiation 
during a normal immune response, and IL-4-driven Th2 cells direct host responses 
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against parasitic infections.  IL-4 is also involved in the development of immune diseases 
such as allergy, autoimmunity and cancer 28.  Both IL-4 and IL-13 signal via the IL-4Rα, 
a component of type I (IL-4Rα and γ chain) and type II receptors (IL-4Rα and IL-13Rα1).  
IL-4 signals via both type I and II receptor pathways, but IL-13 signals only via the type II 
IL-4R.  IL-13 also binds to the IL-13Rα2 chain.  The γ chain activates Janus kinase 
(JAK)3, whereas IL-13Rα1 activates tyrosine kinase 2 (TYK2) and JAK2.  STAT-6 is 
then phosphorylated by activated JAK.  Phosphorylated STAT-6 becomes a dimer and 
moves to the nucleus, and then binds to promoters of the IL-4 and IL-13 responsive 
genes, such as those associated with Th2 cell differentiation, airway inflammation, 
airway hyperresponsiveness (AHR) and mucus production. 
TRAF6 has important roles in innate and adaptive immunity 
TRAF6 has an important function in maintaining central tolerance as well as peripheral 
immunity.  TRAF6 has different roles in T lymphocyte activation and differentiation  
(Scheme 5).  After TCR stimulation, TRAF6 negatively regulates PI3K-Akt activation and 
inhibits IL-2 production and proliferation by enforcing a requirement for costimulation.  
Absence of TRAF6 expression in T cells leads to cell resistance to Treg-mediated 
suppression, and as a result, anergy is not induced due to decreased expression of the 
pro-anergy factor Cbl-b.  TCR-dependent activation of NF-κB is critical for both T cell 
activation and differentiation, and there is evidence that TRAF6 is necessary to activate 
this pathway. TRAF6 is a central regulator of IL-17R signaling and of Th17 
differentiation, and is also essential in memory CD8+ T cell differentiation in response to 
Listeria infection.  It has many important regulatory roles in dendritic cell (DC) biology, 
including activation, survival, homeostasis, and tolerance 29. Lomaga et al. confirmed a 
crucial role of TRAF6 in IL-1 and CD40 signaling, and also showed an unanticipated 
TRAF6 requirement in both LPS signaling and bone metabolism 30.  TRAF6 
ubiquitination is essential for NF-κB and MAPK activation, and we will briefly discuss its 
ubiquitination. 
Protein ubiquitination is an important post-translational process that can affect protein 
targets in different ways, including degradation through the proteasome, change in 
cellular location, modified activity, and promotion or inhibition of protein interactions 31–33.  
Proteins are ubiquitinated by the consecutive action of three enzymes, a ubiquitin-
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activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin ligase (E3). 
Of these, E3 ligases bind specifically to target protein, and the tripartite motif (TRIM) 
family proteins are a large subgroup of E3 ligases. 
 
 
 
 
 
 
 
 
SCHEME 5 |  The roles of TRAF6 in T lymphocyte activation and differentiation.  After TCR stimulation, 
TRAF6 regulates PI3K-Akt and NF-κB activation.  TRAF6 also regulates IL-17R signaling and Th17 
differentiation.  Treg cell expansion and expression of FoxP3 are TRAF6-dependent in peripheral immune 
tissues in vivo.  In response to Listeria infection, TRAF6 is important in memory CD8+ T cell differentiation. 
By targeting TRAF6, Zhao et al. identified TRIM38 (also known as RoRet) as a negative 
feedback regulator in TLR signaling.  TRIM38 binds to TRAF6 and promotes K48-linked 
polyubiquitination, leading to TRAF6 proteasomal degradation in macrophages 34.  The 
TRAF family member-associated NF-κB activator (TANK) inhibits TLR-induced NF-κB 
and AP-1 activation by suppressing TRAF6 ubiquitination in macrophages 35. 
TRAF6 is recruited to the T cell immunological synapse and interacts with LAT to 
activate T cells, and LAT is ubiquitinated at Lys88 via the K63-linked chain.  In addition, 
TRAF6 is needed for and synergizes with LAT to promote TCR/CD28-induced activation 
of NFAT. These TRAF6 functions, distinct from its role in TCR-induced NF-κB activation 
36.  NEMO is ubiquitinated at K399 by MALT1, but MALT1 has no known E3 domain 37. 
MALT1 recruits TRAF6 through its TRAF6-binding sites, leading to NEMO ubiquitination 
by TRAF6 38.  MALT1 also promotes TRAF6 auto-ubiquitination, which then recruits the 
TAK1/TAB2 adaptor protein complex to activate IKK 39. 
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Tolerance and autoimmunity 
A major challenge encountered by the immune system is to react to foreign substances, 
such as microbes while simultaneously tolerating self.  Loss of this balance promotes 
autoimmunity.  Regulatory T cells (Treg) help to maintain this balance 40. Depending on 
where it is induced, there are two types of tolerance, central (in the thymus and bone 
marrow) and peripheral (in other tissues and lymph nodes).  In central tolerance, the 
immune system learns to distinguish self from non-self, and peripheral tolerance is 
central to prohibiting hyperreactivity of the immune system to various environmental 
entities (allergens, gut microbes, etc.).  Tolerance fails due to the interaction of a specific 
environment with specific genes, resulting in autoimmune diseases such as systemic 
lupus erythematosus (SLE), rheumatoid arthritis, type 1 diabetes, autoimmune 
polyendocrine syndrome type 1 (APS-1), among others 41. 
Central tolerance 
Central tolerance is established by deleting autoreactive lymphocytes before they 
become fully immunocompetent.  This occurs during lymphocyte development in 
the thymus and bone marrow for T and B lymphocytes, respectively.  In these tissues, 
maturing lymphocytes are exposed to self-antigens presented by medullary thymic 
epithelial or DC, or by bone marrow cells.  Lymphocytes that that bind strongly to self-
antigens are eliminated by induction of apoptosis or of anergy, a state of non-activity. 
Peripheral tolerance 
Peripheral tolerance is established after T and B cells mature and enter the peripheral 
tissues and lymph nodes.  Its mechanisms normally involve control at the level of T cells, 
especially CD4+ helper T cells, which coordinate immune responses and give B cells the 
confirmatory signals they need to produce antibodies.  The Treg are the cells that mediate 
peripheral tolerance.  Other regulatory immune cells such as TR1 cells that make IL-10 
but do not express FoxP3, TGF (transforming growth factor)-β-secreting TH3 cells, as 
well as other less well-characterized cells that help establish a local tolerogenic 
environment 42. 
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Mitochondrial ROS production and T cell activation 
T lymphocytes are among the immune system components most affected by aging. 
Reactive oxygen species (ROS) are involved extensively in T cell hyporesponsiveness, 
apoptosis, and activation, and the source, kinetics, and localization of ROS production 
all influence cell responses. Characterization of the precise mechanisms by which ROS 
are implicated in the regulation of T cell functions is thus important for understanding the 
immune response, which will allow the development of new therapeutic treatments for 
immune-mediated diseases 43. 
Mitochondrial ROS (mROS) levels are essential for biological effects.  For cellular 
processes such as proliferation and differentiation, low mROS levels are needed.  
Induced mROS production leads to adaptive programs such as transcriptional 
upregulation of antioxidant genes.  Even higher ROS levels will signal the initiation of 
senescence and apoptosis.  At the highest levels of cellular ROS, only non-signaling and 
constant damage to cellular components is observed 44. 
Mitochondrial ROS produced by the electron transport chain are necessary for 
appropriate T cell activation, as demonstrated by studies using the mitochondrial 
complex I inhibitor rotenone, which reduces IL-2 production by activated Th cells 45.  
Increased Ca+2 influx that is maintained by the mitochondria at the immunological 
synapse (IS) as well as mROS production, promote the activation of key transcription 
factors that regulate T cell function. 
AKT activity in stimulated T cells is higher than in naïve, ‘resting' T cells.  AKT stimulates 
glycolysis by inducing surface expression of the glucose transporter Glut-1, and 
increases activity of the glycolytic enzymes phosphofructokinase and hexokinase.  
Hexokinase is further induced by ERK in response to TCR activation.  AKT also 
activates mTOR (mammalian target of rapamycin) signaling to promote protein 
synthesis, as well as ATP citrate lyase to promote lipid synthesis 46. 
Formation of the IS between Th cells and antigen-presenting cells is essential for Th cell 
activation.  After stimulation, the distance between the IS and mitochondria decreases; 
consequently, mitochondria near the IS take up more Ca2+ than those farther away.  
Redistribution of mitochondria to the IS is necessary to maintain Ca2+ influx across the 
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plasma membrane and for Ca2+-dependent Th cell activation.  These results show that 
mitochondria are part of the signaling complex at the IS and their localization near the IS 
is needed for Th cell activation 47. 
After growth factor stimulation of RTK, ROS can trigger activation of signaling pathways 
in cell migration and invasion-like members of the MAPK family – ERK, c-jun NH-2 
terminal kinase (JNK) and p38 MAPK.  ROS can also induce migration by enhancing 
phosphorylation of the p130Cas focal adhesion kinase (FAK) and paxillin 48.  ROS 
induce transcription factors and modulate signaling molecules involved in angiogenesis 
(Matrix metalloproteinase; MMP, Vascular Endothelial Growth Factor; VEGF) and 
metastasis (upregulation of AP-1, CXCR4, AKT and downregulation of Phosphatase and 
tensin homolog; PTEN) 49. 
Main mechanisms for (mROS) generation 
In the electron transport chain (complex I and II), electrons (e−) can be obtained by 
substrate reduction.  Superoxide (O2−) is generated principally from complex I and III; 
complex II and IV also produce a small amount.  Ubiquinone (Q) reduction to ubiquinol 
(QH2) leads to electron transfer to cytochrome c (Cyt C).  Cytochrome b (Cyt b) oxidizes 
synthesized semi-ubiquinone (Q*) to ubiquinone again, and O2− can be generated by 
electron transfer to oxygen.  Rotenone (Rot) inhibits mROS on the level of complex I 
(O2− generation), and diphenyleneiodonium (DPI) also supresses mROS production on 
complex I (NADH-quinone oxidoreductase) and complex II (succinyl dehydrogenase) 
(Scheme 6)50. 
 
 
 
 
 
SCHEME 6 |  The main mechanisms for (mROS) generation. SOD, superoxide dismutase; H2O2, 
hydrogen peroxide; ONOO−, peroxynitrite; NO, nitric oxide. Only the inner mitochondrial membrane is 
represented (adapted from Camello-Almaraz et al., 2006). 
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p21 is more than a cell cycle inhibitor 
p21Cip1 (alternatively p21Waf1) is encoded by the CDKN1A gene located on 
chromosome 6 (6p21.2) in humans.  The p21 gene encodes a 164-amino-acid protein 51.  
p21 can be regulated post-translationally through phosphorylation events that affect the 
stability, degradation rate, localization and activity of the protein.  p21 can be 
phosphorylated by cyclin E-CDK2 at Ser130, which leads to decreased p21 stability via 
ubiquitin-dependent degradation 52.  In contrast, JNK and p38 phosphorylate p21 at 
Ser130 and increase p21 stability and translation 53.  p21 expression can be regulated by 
various transcription factors, which can act as p21 activators, like NF-κB in T cell 
leukemia 54 or p300 in osteosarcoma 55, or as suppressors such as TBX1 in DiGeorge 
syndrome 56, or TBX2/3 in breast cancer 57.  Different biological roles have been reported 
for p21 (Scheme 7), such as cell cycle inhibition, senescence and aging, apoptosis, 
induced pluripotent stem (iPS) cell reprogramming, DNA repair and differentiation 1,2. 
p21 is a negative regulator that maintains cells in G0 phase when conditions for cell 
cycle progression are suboptimal.  p21 is a cyclin-dependent kinase inhibitor that inhibits 
CDK2 and CDK1 complexes.  It is a member of the Kip and Cip families, and arrests 
CDK-cyclin kinase activity on N-terminal sequences.  Furthermore, CDK1 and CDK2 can 
be phosphorylated via activation by p21 and as a result, are inhibited. 
 
 
 
 
 
 
SCHEME 7 |  The central role of p21 in sensing and responding to different stimuli.  p21 reacts to 
distinct stimuli such as oxidative stress, DNA damage, tumor viruses, LPS and cytokines, and responds with 
regulatory effects including inhibition of autoimmunity, cell cycle arrest, DNA repair, and regulation of 
macrophage activation. These effects are in part independent of CDK2 inhibition. 
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p21 acts as a general inhibitor of various DNA repair pathways and inhibits DNA 
synthesis.  This function is mediated by interaction with PCNA (carboxy end) and 
eventually competes for DNA polymerase-δ and other proteins. 
p21 might act as an apoptosis inhibitor in the cytoplasm in response to pro-apoptotic 
factors 58.  The cytoplasmic location of p21 leads to cell survival, which is associated with 
its phosphorylation 59.  p21 phosphorylation by protein kinase A (PKA) leads to caspase-
3 inhibition and as a result, Fas-mediated apoptosis is suppressed 60.  In Ewing tumor 
cells, p21 mediates apoptosis inhibition effect of TNFα-induced NF-κB 61; this process is 
promoted by p21.   p21 degradation by caspase-3 leads to loss of cell cycle inhibition 
effects and, as a result, apoptosis is promoted by TGF-β.  Conversely, p21 induction is 
associated with persistence to apoptosis that is promoted by TGF-β 62. 
Premature aging syndrome in mice and prematurely senescent fibroblasts in man 
showed increased p21 expression 63.  Mice with the protein kinase mutated in ataxia 
telangiectasia (ATM) deficiency and lack of p21 show more apoptosis in lymphoid cells, 
and thus have enhanced tolerance to tumor development 64; p21 thus regulates 
premature senescence.  
Recent studies suggest that the p53-p21 pathway acts as an obstacle in iPS cell 
synthesis, although these cells might bear defective chromosomes due to p53 
underexpression 65. 
p21-activated serine/threonine protein kinases 2 (PAK2) has been identified as a 
positive regulator of TCR signaling.  TCR-promoted upregulation of CD69, activation of 
NFAT and Ca2+ flux are inhibited by PAK2.  PAK2 also slightly affects activation of T 
cells challenged with PMA/ionomycin. These authors showed that the PAK2 effect is 
related to its kinase activity, which is enhanced in response to TCR challenge; finally, 
they found that in primary T cells, dominant-negative PAK2 suppresses IL-2 production 
and CD40L expression 66. 
p21 has an important role in HIV-1 infection.  Lack of p21 in CD4+ T cells of elite 
(infection-free) HIV-exposed individuals leads to an increase in viral transcriptase and 
mRNA production and thus, enhanced CDK9 activity.  p21 inhibits the CDK needed for 
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HIV-1 replication and suppresses HIV-1 infection in CD4+ T cells, which can provide 
treatment strategies for HIV infection 67. 
Mice that lack p21 develop normally and their cells progress through the cell cycle with 
no evident abnormalities.  Whereas p21-deficient T cells usually respond to polyclonal 
T stimulants, they show a clear proliferative advantage over control cells after prolonged 
stimulation with high IL-2 levels, as well as an increased proportion of cells in S phase of 
the cell cycle.  It is evident that cell proliferation is an obligatory process for immune 
system function 3. 
p21-/- T cells have a significant proliferative advantage over wild-type cells after 
prolonged stimulation, but not after primary challenge.  For this reason, large numbers of 
CD4+ memory cells accumulate in p21-deficient mice, which develop loss of tolerance to 
nuclear antigens.  Similar to human lupus, in female p21-deficient mice, anti-dsDNA 
antibodies, lymphadenopathy, and glomerulonephritis are enhanced, leading to 
decreased viability.  These data show a specific role for p21 in the control of T cell 
proliferation, tolerance to nuclear antigens, and female-prone lupus 4. 
The p21 requirement in the control of activated/memory T cells proliferation suggests 
that p21 controls proliferation of activated/memory T cells and that, in addition to 
apoptosis, p21 regulation of cycling comprises an unreported pathway for T cell 
homeostasis.  Concurring with this view, p21-/- mice accumulate memory CD4+ T cells, 
which shows increased proliferative potential after TCR stimulation.  p21 controls the 
proliferation only of activated/memory T cells, which suggests that p21 forms a part of 
the memory T cell homeostasis mechanism, and thus contributes to maintenance of 
tolerance 5.  
Using T cells from p21-/- mice, our lab found that p21 regulates activation of repeatedly 
stimulated effector/memory T cells in a cell cycle-independent manner, but has no effect 
on naïve T cells.  A previously undescribed role for p21 was also found in the control of 
T cell activation via downstream MAPK and NF-κB pathways in cytoplasm.  Lack of p21 
led to ERK1/2 and NF-κB hyperactivation in memory T cells, at late time points after 
second stimulation (unpublished data). 
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In T cells, lack of early growth response gene 2 (Egr-2) leads to impaired p21 
expression, but IFN-γ and IL-17 expression are enhanced; these data indicate that Egr-2 
regulates T cell proliferation as well as inflammation.  These results further confirmed 
p21 activity as an inhibitor of self-reactive T cells and autoimmunity 68. 
Direct evidence showed a p21 role in the control of autoimmune T cell autoreactivity, 
with no effect on normal T cell responses. Using C57BL/6, C57BL/6/lpr and MRL/lpr 
mice that overexpress p21 in T cells, our lab found decreased autoreactivity and 
lymphadenopathy in C57BL/6/lpr mice, as well as lower mortality in MRL/lpr mice.  p21 
inhibited effector/memory CD4+CD8+ and CD4-CD8- lpr T cell accumulation without 
altering defective lpr apoptosis.  This was linked to a previously unreported p21 function 
in limiting T cell hyperactivation and overproduction of IFN-γ, a key cytokine in lupus.  
p21 has no effect on normal T cell responses, indicating differential p21 requirements for 
regulation of autoreactive and normal T cell activity 6. 
p21 and roles in macrophages 
Lack of p21 increases inflammatory cytokine production as well as IKK complex activity 
and NF-κB activation, which lead to macrophage hyperactivation.  Increased sensitivity 
to LPS-induced septic shock was found in p21-/- mice due to increased TNF-α 
production.  Macrophage activation via NF-κB induction is essential for defense against 
pathogens, but also controls inflammatory disease.  Negative regulators attenuate 
macrophage-activating mechanisms to maintain a balanced innate immune response.   
Based on these observations, our lab reported that p21 acts as a negative regulator of 
macrophage activity, independently of its classical role as a cell cycle inhibitor 7. 
p21 is a negative regulator of macrophages.  Analysis of p21-deficient mice showed 
enhanced IL-1β levels, which leads to senstivity to endotoxic shock.  This p21 function is 
related to its CDK-binding domain and is important in inflammation inhibition 69.  Lack of 
p21 also leads to inflammatory arthritis, with enhanced macrophages number and 
intensive articular damage 70. 
In a recent study, our lab showed that p21 is a regulator of macrophage M1-to-M2 
reprogramming and regulates IFN-β, a key cytokine in the control of this process.  p21-
deficient macrophages are unable to develop tolerance, a condition that leads to their 
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death.  p21 mediates inhibitory p50-p50 binding to DNA.  Lack of p21 thus decreases 
the binding affinity of primary and secondary LPS-challenged macrophages, which are 
unable to reduce IFN-β production, leading to an M2-like hyporesponsive state.  These 
findings were confirmed by detection of high p21 levels in sepsis patients, which is 
related to low IFN-β expression.  Knockdown of p21 in human monocytes verified its role 
in IFN-β regulation.  p21 thus regulates macrophage plasticity in LPS tolerance by 
controlling the balance between p65-p50 and p50-p50 NF-κB pathways. The results 
showed that p21 is an important regulator of the balance between inflammatory and 
hyporesponsive states in macrophages 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCHEME 8 |  p21 regulates innate and adaptive immunity.  p21 negatively regulates macrophage 
activation.  Lack of p21 leads to increased IKK complex activity and NF-κB activation in macrophages.  p21 
also regulates macrophage reprogramming by shifting the balance between active p65-p50 and inhibitory 
p50-p50 NF-κB pathways.  In T cells, p21 is a negative regulator of effector/memory CD4+ T cell expansion.  
p21 overexpression reduces IFN-γ production in CD4+ T cell in C57BL/6/lpr and MRL/lpr mice. 
 
 
p21 is thus considered a central regulator of immunity that controls innate and adaptive 
responses and holds the development of autoimmunity at bay 3,5 (Scheme 8). 
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OBJECTIVES 
 
 
Various biological roles have been reported for p21, including cell cycle inhibition, 
senescence and aging, apoptosis, induced pluripotent stem cell (iPS) reprogramming, 
DNA repair and differentiation 1,2.  p21-deficient T cells have an important proliferative 
advantage compared to wild type (WT) cells after prolonged IL-2 stimulation 3.  Lack of 
p21 leads to unusually high accumulation of CD4+ memory cells, which leads to 
development of loss of tolerance to nuclear antigens 4.  p21 only controls the 
proliferation of activated/memory T cells, which suggests that p21 is a part of the 
memory T cell homeostasis mechanism, and contributes to maintenance of tolerance 5.  
Previous studies in our lab using C57BL/6/lpr and MRL/lpr mice overexpressing p21 in T 
cells identified decreased autoreactivity and lymphadenopathy in C57BL/6/lpr, as well as 
reduced mortality in MRL/lpr mice.  These data show direct evidence for a p21 role in 
controlling autoimmune T cell autoreactivity without affecting normal T cell responses 6.  
p21 acts as a negative regulator of macrophage activity, independently of its classical 
role as a cell cycle inhibitor 7.  We recently showed that p21 regulates the equilibrium 
between p65-p50 and p50-p50 NF-κB pathways to mediate macrophage plasticity in 
LPS tolerance 8.  Although these studies identify p21 as a negative regulator of innate 
and adaptive immunity, the mechanism by which p21 affects T cell responses remained 
unknown. 
We undertook studies to describe the role of p21 in T cell activation, and defined the 
following objectives: 
1. To describe the mechanism by which p21 controls effector/memory (memory-
like) CD4+ T cell activation via TCR stimulation, 
2. To examine the effects of p21 on IFN-γ production after repeated TCR 
stimulation, 
3. To determine whether p21 influences memory-like T cells in a TCR-independent 
manner and its role in IFN-γ production, 
4. To study the role of p21 in mitochondrial reactive oxygen species production in 
memory-like CD4+ T cells, and 
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5. To analyze how p21 affects IFN-γ production of p21-/-/lpr mouse T cells. 
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   Materials and methods  
Mice 
C57BL/6 (B6 or WT) control mice were from Harlan Interfauna Ibérica (San Felíu de 
Codines, Barcelona, Spain); C57BL/6-p21tg (transgenic) mice were a kind gift from Dr. 
Arun Fotedar (Sidney Kimmel Cancer Center, San Diego, CA).  FAS-negative C57BL/6-
lpr (B6/lpr) and MRL-lpr mice were obtained from Jackson Laboratories.  C57BL/6-lpr-
p21-/- mice (B6/lpr-p21-/-) were generated by crossing C57BL/6-lpr with C57BL/6-p21-/- 
mice.  C57BL/6-p21-/- mice (p21-/- or KO) were generated by crossing p21-/- 129/Sv mice 
(laboratory of Dr. Gregory Hannon, Cold Spring Harbor Laboratory, NY, USA) with 
C57BL/6 mice for eight generations.  Background analysis via microsatellite markers 
confirmed >99% identity with the B6 background 71.  C57BL/6-lpr-p21tg mice were 
generated from C57BL/6-lpr and C57BL/6-p21tg mice.  MRL-lpr-p21tg mice were 
generated by backcrossing C57BL/6-p21tg with MRL-lpr mice for more than nine 
generations.  In C57BL/6-lpr-p21tg and C57BL/6-lpr-p21tg mice, transgene expression 
was restricted to T cells by the proximal Lck promoter 72.  B10BR mice were from Jackson 
Laboratory and have an MHC I-Ak haplotype. Tg 5CC IAK mice were obtained from Mark Davis 
laboratories. Tg 5CC IAK-p21-/- mice were generated by crossing Tg 5CC IAK with C57BL/6-
p21-/- mice. 
When used for macrophages, B6 and p21-/- mice were maintained in the animal facility 
barrier zone to avoid contact with pathogens. 
Eight- to ten-week-old mice were used in most experiments.  All mice were maintained in 
the CNB animal facility.  Experiments were performed in accordance with national and 
European regulations, and were approved by the CNB Bioethics Committee.	
Cell culture 
The spleen was removed from mice, splenocytes isolated, and erythrocytes were lysed 
by treatment with lysis buffer containing ammonium chloride (0.83% NH4Cl, 0.1% 
KHCO3 and 0.004% EDTA; 4 min at room temperature (RT)).		CD4+ T cells were purified 
by the negative isolation method (Mouse CD4 Negative Isolation Kit, Dynal Biotech) 
using antibody-coated Dynabeads to bind CD8+ T cells and B cells.  After 30-40 min 
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incubation (4ºC, with rotation), a magnetic field was applied to separate CD4+ T cells. 
Normally, >80% pure CD4+ T cells were obtained, as confirmed by flow cytometry. 
Purified CD4+ T cells were cultured in RPMI-1640 medium supplemented with 2 mM 
L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin-streptomycin, 50 mM 
β-mercaptoethanol, 10 mM HEPES pH 7.4, 0.1 mM nonessential amino acids (all from 
Gibco) and 10% FBS (fetal bovine serum; Harlan Bioproducts).  The cells (106/ml) were 
stimulated in vitro with 1.5 µg/ml concanavalin A (ConA, Sigma) in medium 
supplemented with 20 ng/ml human recombinant interleukin 2 (rIL-2; PeproTech) for 
1 day.  In some experiments, cells were stimulated with plate-bound anti-CD3 
(PharMingen, 1 µg/ml in PBS) and soluble anti-CD28 (1 µg/ml; PharMingen).  Cells were 
washed and resuspended in medium (0.5 x 106 cells/ml) with 20 ng/ml IL-2 for 6 days, 
then restimulated with 1.5 µg/ ml ConA (106/ml) in the presence of the apoptosis inhibitor 
zVAD (benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone; Bachem) for indicated times 
(Scheme 9).  In some experiments, cells were restimulated with PMA (phorbol 12-
myristate 13-acetate, 12 ng/ml; Calbiochem) and ionomycin (0.5 µg/ml; Sigma), with 
plate-bound anti-CD3 (PharMingen, 1 µg/ml in PBS) and soluble anti-CD28 (1 µg/ml; 
PharMingen), with IL-12 (10 µg/ml) and/or IL-18 (10 µg/ml), or with IL-4 (4 ng/ml), all 
from Sigma Aldrich.	
	
	
	
	
	
	
	
	
SCHEME 9 |  Repeated in vitro stimulation protocol.  Purified mouse CD4+ T cells were stimulated with 
ConA or IL-12 for 24 h, expanded for 6 days in IL-2, and restimulated in different conditions. 
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For macrophage cultures, mice received 1 ml of 3% thioglycollate medium (Difco) 
intraperitoneally.  After 4 days, peritoneal exudate cells (PEC) were collected from the 
peritoneal cavity.  PEC were plated in serum-free RPMI 1640 (2 h) and non-adherent 
cells were discarded by washing with PBS; adherent macrophages were cultured 
overnight in complete RPMI 1640 supplemented with 10% FBS.  Cells were tolerized 
with 100 ng/ml LPS (20 h), washed with PBS, cultured in medium (2 h), and restimulated 
with LPS for indicated times. Control cells were cultured in medium alone. 
Mixed cultures of CD4+ T cells with APC 
To stimulate cells in physiological conditions, mouse CD4+ T cells from tg 5cc IAK and 
p21-/- tg 5cc IAK mice were isolated and purified.  Peritoneal macrophages from B10BR 
IAK mouse were used to present agonist peptides with high affinity (PCC, 
KAERADLIAYLKQATAK; at 3 mM) in a first stimulation.  After	24 h, cells were expanded 
in IL-2 (6 days), followed by restimulation with peptide presented by macrophages for 
indicated times. 
 
 
 
 
 
 
 
SCHEME 10 |  In vitro system of repeated stimulation of CD4+ T cells with APC that present TCR-
specific peptides.  CD4+ T cells from tg 5cc IAK and tg 5cc IAK p21-/- mouse spleens were incubated with 
peptide-presenting macrophages for 24 h, then expanded in IL-2 for 6 days, and restimulated with peptide-
presenting macrophages for indicated times.   
Flow cytometry (fluorescence-activated cell sorting, FACS) 
Cells (0.5-1 x 106) were normally stained in 50 µl antibody mix (in staining PBS; PBS 
with 1% FBS).  Cells were incubated (20 min, 4°C, in the dark), washed in PBS, 
resuspended in 200-300 µl staining PBS and analyzed on a cytometer (FC 500; 
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Beckman Coulter).  Antibodies used for extracellular staining were anti-CD8-PE, -CD44-
FITC, -CD4-FITC, B220-APC (all from Beckman Coulter), -CD62L-APC and  -CD4-
PeCy7 (from eBioscience), -VαPE, -Vβ3-FITC, -Vβ3-PE (all from PharMingen) and 
-I-Ak-FITC (Serotec). 
For intracellular cytokine staining, CD4+ T cells were stimulated (24 h) in medium 
containing IL-12 plus IL-18 in the presence of IL-2.  During the last 3 h of stimulation 
brefeldin A (1X, BioLegend) was added.  To exclude dead cells, cells were stained using 
the violet LIVE/DEAD stain kit (Invitrogen).  Cells were then stained with surface markers 
(anti-CD4-PeCy7, -CD44-APC and CD62L-PE) and washed with PBS, fixed, and 
permeabilized with Cytofix/Cytoperm (Cytofix/Cytoperm-Fixation/Permeabilization kit, BD 
Biosciences) at 4ºC.  After 20 min cells were washed with 1x Perm/Wash buffer and 
blocked with 1 ml Fc-receptor blocking antibody (Beckman Coulter; 15 min, 4°C).  Cells 
were then washed and stained with anti-IFN-γ-FITC (1/100 dilution, eBioscience).  After 
30 min incubation at 4ºC, cells were washed with Perm/Wash (1X) and analyzed on a 
cytometer (Gallios; Beckman Coulter).  FlowJo software was used (Tree Star, Inc.; 
version 8.8.3) for data analysis. 
Proliferation analysis 
[3H] thymidine uptake 
T cells were cultured in 96-well plates for 24 and 48 h.  During the last 16 h of culture, 
1 µCi/well [3H] thymidine (Perkin Elmer) was added.  Cells were transferred onto fiber 
filters (Wallac) using a semi-automatic cell harvester (Wallac).  T cell proliferation was 
measured using a beta-plate counter (b1205 Wallac, Perkin Elmer).  Incorporation of [3H] 
thymidine into DNA is relative to DNA synthesis. 
Cell cycle analysis 
T cells (0.5-1 x 106) were washed with PBS and permeabilized with 50 µl of detergent. 
DNA staining was performed with 400 µl (10 mg/ml) of propidium iodide (PI; both 
reagents from the DNA-Prep Reagent Kit, Beckman Coulter) for 20-30 min at 37ºC.  In 
some experiments, cells were fixed with 70% EtOH (-20ºC, overnight).  Cells were then 
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washed with 1x PBS, incubated with 400 µl PI (20-30 min, 37ºC) and analyzed by flow 
cytometry (FC500, Beckman Coulter).	
Cell viability 
T cells were stained with Trypan blue and live cells were counted.  The number of live 
cells was also used to measure the proliferation ratio. 
Real-time PCR 
T cells were washed with PBS and total RNA was extracted according to the RNeasy 
Mini Kit protocol (Qiagen).  RNA purity and concentration were determined using a 
nanodrop spectrophotometer.  Total RNA (1 mg) was reverse-transcribed with a cDNA 
kit (Appled Biosystems).  Real-time PCR was performed using EvaGreen Master Mix 
(Solis BioDyne) on the ABI PRISM 7900HT (Applied Biosystems).  The products were 
amplified using primers for p21, 5’-GCAGATCCACAGCGATATCC-3’ (forward) and 5’-
CAACTGCTCACTGTCCACGG-3’ (reverse); IFN-γ, 5'-GCAACAGCAAGGCGAAAAAG-3' 
(forward) and 5'-ATCTCTTCCCCACCCCGAAT-3' (reverse); IL-10, 5’-CGGGAAGACAAT 
AACTG-3’ (forward) and 5’-CATTTCCGATAAGGCTTGG-3’ (reverse); β-actin, 5’-GGCT 
GTATTCCCCTCCATCG-3’ (forward) and 5’-CCAGTTGGTAACAATGCCATGT-3’ 
(reverse).  All primers were synthesized, desalted, and purified by Sigma.  To normalize 
each sample, β-actin was used as an endogenous control.  Two independent 
experiments were performed in triplicate. Data were processed using SDS 2.4 software 
(Applied Biosystems). 
Western blot 
T cells (5-6	x 106 cells) were washed with cold PBS and lysed in NP-40 lysis buffer 
(0.2% NP-40, 10 mM Tris-HCl [pH 7.5], 150 mM NaCl) supplemented with complete 
protease and phosphatase inhibitor cocktail (Roche), for 20 min at 4°C. Protein 
concentration was measured using the Bradford assay (Bio-Rad). Lysates (15-20 µg) 
were resolved in 12% polyacrylamide gels. Proteins were then transferred to a 
nitrocellulose membrane (Bio-Rad) for 80 min at 0.3 A.  Membranes were blocked with 
5% BSA or low-fat dry milk in 0.05% Tween 20 (1 h, RT) and incubated overnight (in 
some cases, 2 h) with appropriate primary antibodies (Table 1). Species-specific 
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horseradish peroxidase (HRP)-labeled secondary antibodies (Dako) were then added (1 
h, RT).  Blots were visualized using Western Lightning Plus-ECL (PerkinElmer) and 
quantitated. 
Table 1 |  Antibodies used in western blot and flow cytometry 
Antibody Isotype Source Reference Nº 
p21 Mouse monoclonal IgG2b Santa Cruz 
Biotechnology 
Sc-6246 
p21 Goat polyclonal IgG Sc-397-G 
TRAF6 Rabbit polyclonal IgG Sc-7221 
p50 Mouse monoclonal IgG1 Sc-8414 
p-p50 Rabbit polyclonal IgG Sc-101744 
p65 Mouse monoclonal IgG1 Sc-8008 X 
Ubiquitin Mouse monoclonal IgG1 Sc-8017 
p-STAT4 Rabbit polyclonal IgG Sc-101804 
BCL10 Mouse monoclonal IgG2b Sc-13153 
CARMA1 Mouse monoclonal IgG1 Sc-166910 
p-ZAP70 Rabbit antibody Cell Signaling  2701S 
p-AKT Rabbit monoclonal antibody 3787S 
p-IκBα Mouse monoclonal antibody 9246S 
IκBα Rabbit antibody 9242 
p-ERK Mouse monoclonal antibody 9106S 
p-LCK Rabbit antibody 2751S 
LCK Rabbit antibody 2752S 
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Antibody Isotype Source Reference Nº 
ERK Rabbit antibody Cell Signaling 9102S 
MALT1 Rabbit antibody 2494 
p-p38 Rabbit antibody 9211S 
p38 Rabbit antibody 9212 
p-p65 Rabbit antibody 3031S 
p-PKCθ Rabbit antibody 9377S 
p-FADD Mouse monoclonal antibody 2785L 
Caspase3 Rabbit antibody 9662S 
PARP Rabbit antibody 9542S 
p110-α Rabbit monoclonal antibody 4249 
PTEN Rabbit monoclonal antibody 9559 
Pan p85 Rabbit polyclonal antibody Millipore 06-195 
caspase-8 Mouse monoclonal IgG1 Alexis ALX-804-447-C100 
β-actin Monoclonal  Sigma A3854 
CD4- FITC Rat IgG2a Flow 
cytometry 
Becton Dickinson 553651 
CD8- PE 553033 
B220-APC Rat IgG2a, κ Beckman Coulter 732158 
CD62L-PE eBioscience 11-7311-82 
CD44-PECy5 Rat IgG1, κ Biolegend 103010 
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Immunoprecipitation 
ConA-restimulated T cells were washed with cold PBS and lysed in RIPA buffer (50 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS 
(sodium dodecyl sulfate), 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM dithiothreitol (DTT) supplemented with 
complete protease and phosphatase inhibitor cocktail; Roche) for 30 min on ice.  Equal 
amounts of protein were precleared with Protein G Dynabeads (Invitrogen) and 
incubated overnight at 4°C with appropriate antibody.  The protein-Ab complex was 
incubated with Protein G Dynabeads (1 h, 4°C and rotation).  Beads then were washed 
twice with washing buffer (10 mM Tris-HCl pH 8.0, 1% NP-40, 1 M NaCl, 1 mM EDTA, 
supplemented with complete protease and phosphatase inhibitor cocktail; Roche).  
Proteins were dissociated from beads with SDS-PAGE sample buffer, resolved on 
9-12% acrylamide gels and transferred to a nitrocellulose membrane.  Immunoblotting 
was performed with a protein-specific antibody.  
Ubiquitination assay 
The in vitro ubiquitination assay was performed as described 73. Briefly, macrophage or 
T cell cultures were incubated with proteasome inhibitor MG132 (20 µM; 30 min, 37°C) 
before harvest, washed in PBS/10 µM N-ethylmaleimide (N-EM), lysed in SDS buffer 
(1% SDS, 10 mM Tris-HCl pH 8.0, 150 mM NaCl, supplemented with 
protease/phosphatase) by boiling (5 min), and diluted (1/10) in RIPA buffer (without 
SDS) supplemented with 20 µM N-EM and protease/phosphatase inhibitor cocktail. 
Equal amounts of protein were precleared with Protein G Dynabeads and incubated with 
appropriate antibody.  After SDS-PAGE, proteins were transferred to a nitrocellulose 
membrane, autoclaved (30 min liquid and 10 min solid cycle), and immunoblotted with 
an anti-Ub antibody (P4D1; Santa Cruz Biotechnology) to detect ubiquitination. 
Electrophoretic mobility shift assay (EMSA) 
T cells (10 x 106) were washed with cold PBS and lysed in 500 µl buffer A (10 mM 
Hepes pH 8, 50 mM NaCl, 0.2 mM saccharose, 1 mM EDTA, 0.5 mM spermidine, 
0.15 mM spermine, 0.5% Triton X100, 1 mM PMSF, 2 ng/µl aprotinin, 0.5 ng/µl 
pepstatin, 7 mM β-mercaptoethanol). After incubation (5 min, 4°C), cells were 
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centrifuged, supernatant (cytosolic extract) was separated and the pellet (containing 
nuclei) was washed with 300 µl buffer B (10 mM Hepes pH 8, 50 mM NaCl, 0.1 mM 
EDTA, 25% glycerol, 1 mM PMSF, 2 ng/µl aprotinin, 0.5 ng/µl pepstatin, 7 mM 
β-mercaptoethanol).  After centrifugation, the pellet was incubated (30 min, 4°C) with 
60 µl buffer C (10 mM Hepes pH 8, 350 mM NaCl, 0.1 mM EDTA, 0.5 mM spermidine, 
0.15 mM spermine, 25% glycerol, 1 mM PMSF, 2 ng/µl aprotinin, 1 ng/µl pepstatin, 
7 mM β-mercaptoethanol).  The protein concentration of nuclear extract was determined 
by Bradford assay.  Radioactive labeling of double-stranded probes (200 ng) was carried 
out in 10x T4 kinase buffer and catalyzed by T4-polynucleotide kinase (30 min, 37°C). 
Nuclear extracts (10 µg) were incubated in binding buffer (0.45 µg/µl BSA, 20 mM 
Hepes, 1 mM EDTA, 20% glycerol, 1 M DTT, 0.5 mM PMSF, 1 M MgCl, 0.5 M EDTA 
pH 7, 2 M NaCl, 100 mM Tris-HCl pH 7.5, poly (dI-dC) with 1 µl [γ-32P]-ATP-labeled 
probe containing the required transcription factor consensus sequence (NF-κB: 5´-
AGTTGAGGGGACTTTCCCAGGC-3´, Promega; AP-1: 5´- 
CGCTTGATGAGTCAGCCGGAA-3´, Promega; NFAT: 5´-
GCGCCAAAGAGGAAAATTTGTTTCATA-3´, Santa Cruz Biotechnology).  The labeling 
reaction was catalyzed by T4-polynucleotide kinase and incubated in 10x kinase buffer 
(30 min, 37°C).  Nuclear extracts were incubated (20 min, RT) with radiolabeled probe 
and resolved on 5% acrylamide gel in 0.5x TBE buffer. Gels were dried and exposed to 
X-ray film (Kodak Minolta) at -80°C for up to 17 h.  After development of 
autoradiographs, band intensity of radiolabeled NF-κB-DNA complexes was used to 
measure NF-κB activation.  NF-Y consensus sequence was used as loading control. 
ROS measurement 
To measure the mitochondrial reactive oxygen species (ROS) level, T cells were 
incubated with MitoSOX Red (Invitrogen; 5 mM final concentration, 30 min, 37°C) and 
washed with PBS.  Cells were resuspended in PBS for staining and subjected to flow 
cytometry.  Mitochondrial ROS inhibitor DPI (5 mM, Sigma) was added to cell culture 1 h 
before the stimulus.  To control for baseline fluorescence, samples from each 
experiment were left unstimulated and stained as above.  All samples were processed in 
triplicate. 
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Cloning 
 
Mouse p21 was amplified by PCR using different oligonucleotides (Table 2).  p21 DNA 
and plasmids (pECFP-N1, pYFP-N1, pECFP-C1 and pYFP-C1, all from BD Clontech) 
were digested with restriction enzymes Xho I, Age I and ECOR I (all from New England 
BioLabs; 90 min, 37°C), followed by ligation for 1 h at 18°C in presence of ligase.  
Products were incubated with XL1 Blue bacteria (15 min, on ice), followed by incubation 
in a water bath (1 min, 42°C).  Thereafter, cells were re-incubated on ice (10 min), 
followed by incubation at 37°C with agitation (1 h).  Cells were seeded on Luria-Bertani 
(LB) agar with kanamycin and incubated (24 h, 37°C).  Grown recombinant colonies 
were purified with a plasmid purification kit (Qiagen Miniprep) and purified plasmids were 
confirmed by sequencing. 
Table 2 |  Oligonucleotides used in p21 cloning 
Target Oligonucleotides 
FW XhoI N1 5´-TTCTCGAGATGTCCAATCCTGGTGATGTC-3´ 
Rv AgeI N1 5´-ACCGGTTTACAGGGTTTTCTCTTGCAGAAG-3´ 
FW XhoI C1 5´-AAACTCGAGAAATGTCCAATCCTGGTGATGTC-3´ 
RV ECOR1 C1 5´-GAATTCTCAGGGTTTTCTCTTGCAGAAG-3´ 
 
Transfection 
Functional oligonucleotides (antisense and siRNA) for p21 downregulation were 
designed and synthesized by IMDEA Nanoscience (Madrid, Cantoblanco).  Two types of 
antisense oligonucleotides were prepared to target the p21 gene at regions 141-160 nt 
(antisense 1: 5’-AGACAACGGCACACUUUGC-TTTTT-3’) and 521-540 nucleotides (nt) 
(antisense 2 : 5’-AUAGAAAUCUGUCAGGCUG-TTTTT-3’). 
For siRNA, the sequence of antisense 2 was used.  The desired double-stranded RNA 
structures were obtained by an annealing process of passenger: 5’-CAGCCUGACAGAU 
UUCUAU-TTTTT-3’) and guide: 5’-AUAGAAAUCUGUCAGGCUG-3’ and for scrambled, 
passenger: 5’- GUUGGAGCUGAUGGCGUAG-TTTTTT-3’ and guide:  5’-CUACGCCAU 
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CAGCUCCAAC-TT-3’.  In addition, sequence, 5’-TTTTTTTTTTTT-fluorescent-3’ was 
used as a nonsense sequence (poly T).  The synthesized oligonucleotides were 
conjugated to gold nanoparticles (AuNP). 
Double strand siRNA synthesis was confirmed by high-resolution melt (HRM) analysis 
(see Methods figure). 
 
Transfection by gold nanoparticles 
Transfection was carried out after 5 days IL-2 expansion.  Cells (5-6 x 106 cells) were 
transfected with different concentrations of oligonucleotides conjugated to AuNPs 
(100-200 nm siRNA/time point and 0.1-1 µm antisense/time point) in complete serum-
free medium with no antibiotics.  At 4-24 h after transfection, the cells were washed and 
restimulated with ConA in the presence of zVAD (25 µM) in complete medium for 
indicated times.  A nonsense sequence (poly T) and a scrambled sequence, both 
conjugated to gold nanoparticles, were also used as controls. 
 
 
 
 
 
 
 
 
Methods Figure |  DS siRNA was confirmed by HRM.  Different concentrations of synthesized siRNAs 
were analyzed by qPCR (HRM) for double strand.  Single strand DNA was used as control.  Representative 
data are shown (n = 3). 
Transfection by Amaxa kit 
T cells were also transfected with siRNA against p21 using a conventional method 
(Amaxa-Lonza Mouse T-cell Nucleofector kit, VPA-1006) as a control, according to 
manufacturer’s instructions.  Briefly, 5-6 x 106 cells were centrifuged and resuspended in 
4D Nucleofector solution and transfected with same concentration of antisense and 
siRNA as AuNP in the medium provided.  Cells were then electroporated by 
4D-Nucleofector X Unit and resuspended with pre-warmed fully supplemented Mouse 
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T cell NucleofectorM medium.  At 4-24 h post-transfection, cells were restimulated with 
ConA in the presence of zVAD.  A nonsense sequence (poly T) and a scrambled 
sequence were used as controls.  This method (electroporation) also was used for 
plasmid transfection. 
Confocal analysis 
CD4+ T cells were transfected with YFP plasmids containing p21, using Nucleofector Kits 
for Mouse T Cells (Lonza).  Cells were cultured on poly-L-lysine coated chamber slides 
in 24-well dishes.  At 4-24 h after transfection, the cells were restimulated with ConA. To 
terminate stimulation, cells were placed at 4°C, washed, fixed and mounted with DAPI 
(blue)-containing mounting medium (Vectashield; Vector Laboratories) for confocal 
microscopy (Olympus). 
Annexin-V assay 
Cultured cells harvested at the indicated time were washed twice with cold PBS and 
resuspended in 1X Binding Buffer (Southern Biotechnology) at a concentration of 1 x 106 
cells/ml.  Cells were stained with 5 µl/100 FITC annexin-V and incubated (15 min, 4ºC). 
To distinguish live from apoptotic and necrotic cells, 10 µl PI stock solution was added 
before flow cytometry analysis. 
Statistical analyses 
Statistical significance was determined with	 the Student’s t test, one-way ANOVA, two-
way ANOVA (with Bonferroni correction), or Mann-Whitney U test, as indicated.  All 
statistical analyses were performed using Prism 6.0 software (GraphPad).  p values 
<0 .05 were considered significant. 
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RESULTS 
 
Preamble 
The p21 role in macrophage activation suggests that p21 regulates 
T cell activation 
 
In previous studies, our laboratory determined that p21 is involved as a negative 
regulator in macrophage activation by triggering the IKK complex and NF-κB activation 7.  
In a later study that revealed a p21 role in the regulation of M1-to-M2 polarization 8, we 
analyzed the mechanisms by which p21 affects macrophage reprogramming, and 
extend our previous studies related to the p21 effect on macrophage activation. 
 
 Lack of p21 reduces DNA-binding affinity of inhibitory p50-p50 NF-κB 
homodimers 
 
 As p21 regulates M1-to-M2 polarization by increasing the p50-p50 balance, we explored 
how p21 regulates the balance between p65-p50 and p50-p50 NF-κB dimers in tolerized 
mouse macrophages, and whether these events are related to enhanced p50 
ubiquitination.  We next examined whether p21 affects p50 ubiquitination.  We found a 
notable decrease in p50 ubiquitination in p21-deficient compared with WT macrophages 
at 30 min and 1 h after LPS rechallenge (Figure 1A).  Reduced ubiquitination in p21-
deficient macrophages is associated with lower ratios of DNA-bound p50-p50 at these 
times.  As DNA binding precedes p50 ubiquitination 75, we considered that p21 
deficiency could reduce p50-p50:DNA binding affinity, leading to decreased p50 
ubiquitination.  Efficient DNA binding of p50-p50, but not of p65-p50, is linked to p50 
phosphorylation 74.  Indeed, p50 phosphorylation was decreased in p21–/– macrophages 
at 15 min after LPS rechallenge (Figure 1B), which indicates that p21 deficiency reduces 
p50-p50 DNA binding affinity.  Overall, we identified p21 as positive regulator of p50 
ubiquitination. 
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FIGURE 1 |  p21 regulates p50-p50 NF-κB DNA binding.  A. Reduced ubiquitination of p50 in P21-/- LPS-
tolerized/restimulated peritoneal macrophages.  Equal amounts of protein were immunoprecipitated with 
anti-p50 antibody and tested in Western blot with antibody to ubiquitin.  n.c., negative control; IP performed 
in the absence of cell extracts.  B. Reduced p50 phosphorylation in p21-/- LPS tolerized/restimulated 
peritoneal macrophages.  Equal amounts of protein were immunoprecipitated with anti-p50 antibody and 
tested in Western blot with anti-phospho-serine/threonine antibody.  Representative gels of at least two 
experiments performed. 
 
p21 regulates TRAF6 ubiquitination in macrophages after LPS rechallenge 
As we showed that p21 has an effect on the ubiquitination efficiency of p50-p50, we 
consider that it could affect other proteins with important roles in macrophage activation, 
such as TRAF6. 
TRAF6 and its ubiquitination have a central function in macrophage activation; indeed, 
suppression of TRAF6 ubiquitination leads to reduced NF-κB and AP-1 activation in 
macrophages 36.  Here we studied whether p21 affects TRAF6 ubiquitination.  TRAF6 
ubiquitination was reduced in p21-deficient compared with WT macrophages at 15 and 
60 min after LPS rechallenge (Figure 2), which shows that p21 induces TRAF6 
ubiqiutination. 
 Overall, p21 is an important factor that regulates macrophage activation after LPS 
rechallenge.  We therefore tested the role of p21 in CD4+ T cell activation after TCR-
dependent and -independent restimulation. 
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FIGURE 2 |  Reduced TRAF6 ubiquitination in p21-/- LPS-tolerized/restimulated peritoneal 
macrophages.  Equal amounts of protein were immunoprecipitated with anti-TRAF6 antibody and 
developed in Western blot with antibody to ubiquitin.  n.c., negative control; IP performed in the absence of 
cell extracts.  Representative gels of two experiments are shown. 
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Chapter 1: p21 regulates TCR-dependent activation of memory-like T cells 
 
Previous studies from our laboratory showed that p21 regulates T cell responses after 
repeated stimulation, but not those of naïve T cells.  It was initially assumed that this was 
associated to the p21 effect in inhibiting the cell cycle.  A role for p21 in T cell activation 
was later suggested. 
p21 is a negative regulator of memory-like CD4+ T cells after repeated stimulation 
p21 regulates proliferation and activation of repeatedly stimulated effector/memory 
(memory-like) T cells in a cell cycle-independent manner, but has no effect on naïve 
T cells.  The mechanism underlying this effect was unknown.  For our study, we 
designed a cell culture protocol to obtain memory T cells.  CD4+ T cells were stimulated 
with ConA in the presence of IL-2.  After 24 h, the cells were expanded in IL-2 for 6 days 
and then restimulated with concanavalin A (ConA) in the presence of a caspase 8 
inhibitor, zVAD (Figure 3A).  Cell cycle analysis showed more proliferation of p21-/- cells 
(Figure 3B).  In an immunoblot assay, we found that p21 expression increased at 2 h 
post-ConA restimulation.  In addition, ERK1/2 and p38 were hyper-phosphorylated in 
p21-/- T cells at early time points (Figure 3C). 
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FIGURE 3 |  p21 deficiency enhanced memory-like CD4+ T cell  activation after secondary stimulation. 
A. In vitro repeated stimulation protocol.  CD4+ T cells purified from mouse spleen were stimulated with 
ConA (1.5 µg/ml), expanded with IL-2 (20 ng/ml) and restimulated with ConA in the presence of zVAD 
(25 µM).  B. Cell cycle analysis at 24 h after second stimulation showed more proliferation in p21-/- T cells.  
C. Western blot showed ERK1/2 and p38 hyper-phosphorylation in p21-/- T cells at early times after 
secondary TCR challenge.  p21 was expressed in B6 (WT control) T cells.  β-actin was used as loading 
control. In all cases, representative data are shown (n = 5). 
 
Lack of p21 enhanced activity of elements involved in the T cell activation 
pathway in response to specific TCR peptides 
Using TCR activation through ConA stimulation, we found that p21 is important for T cell 
activation.  We next tested the p21 regulatory effect on T cell responses to antigens in 
physiological conditions, by stimulation with a specific antigen.  We used T cells from 
transgenic (tg) 5cc IAK and p21-/- tg 5cc IAK mice.  Purified control and p21-deficient 
CD4+ T cells were cultured with B10BR mouse macrophages as antigen-presenting cells 
(APC).  The mixed cell culture was stimulated with a specific peptide (PCC) for 1 day 
and then expanded in the presence of IL-2 for 6 days.  Cells were exposed to new 
macrophages, followed by a second stimulation with the same peptide as indicated 
(Figure 4A).  Proliferation was tested by [3H] thymidine incorporation 24 h after 
secondary peptide challenge, which showed higher proliferation levels in p21-deficient 
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mice (Figure 4B).  Western blot analysis indicated similar protein expression as detected 
by TCR-dependent (ConA) stimulation.  Hyper-phosphorylation of ERK1/2 and p38 was 
identified in p21-deficient memory T cells after the second stimulation (Figure 4C). 
	
FIGURE 4 |  In vitro system of repeated stimulation of CD4+ T cells with APC that present TCR-
specific peptides.  A. CD4+ T cells from tg 5cc IAK and tg 5cc IAK p21-/- mouse spleens were incubated 
with peptide-presenting macrophages for 24 h, then expanded in IL-2 for 6 days, and restimulated with 
peptide-presenting macrophages for indicated times.  B. [3H] thymidine uptake 24 h after secondary peptide 
challenge showed enhanced proliferation of p21-/- T cells.  C. Western blot showed increased pERK and 
p-p38 protein levels involved in T cell activation.  β-actin was used as loading control.  Representative data 
are shown (n = 2). 
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Lack of p21 does not affect T cell activation after primary challenge 
As we found that p21 regulated T cell activation after secondary stimulation, we tested 
whether p21 also affects naïve T cell activation.  Data analysis showed p21 expression 
at 24 h post-ConA challenge, which did not affect T cell activation markers such as 
p-ERK (Figure 5A).  Cell cycle analysis showed similar proliferation in both WT and p21-/- 
cells (Figure 5B). 
 
 
 
 
 
 
 
 
 
 
FIGURE 5 |  p21 does not influence naïve CD4+ T cell activation.  CD4+ T cells purified from mouse 
spleen were ConA-stimulated for indicated times in the presence of zVAD.  A. Western blot showing p21 
expression and ERK phosphorylation.  β-actin was used as a loading control.  B. Cell cycle analysis at 24 h 
after stimulation.  Representative data are shown (n = 4). 
 
p21 deficiency affects several modulators of the involved in T cell activation 
pathway  
As we found more activation of memory CD4+ T cells after secondary stimulation, we 
determined the p21 effects on other molecules with central roles in T cell activation 
pathways.  Western blot analysis of memory-like T cells after ConA restimulation showed 
more AKT, PKCθ and p65 phosphorylation, and an increase in CARMA1, BCL10 and 
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TRAF6 levels in p21-/- T cells at indicated times (Figure 6).  These data showed that p21 
effects on activation-associated molecules, which supports its role in T cell activation.  
We also tested whether p21 influences these molecules after primary stimulation.  
Results showed similar phosphorylation and protein levels in both WT and in p21-
deficient naïve CD4+ T cells (Figure 7). 
 
 
 
 
 
 
 
 
 
 
FIGURE 6 |  p21 deficiency enhanced activity of elements involved in the T cell activation pathway 
after secondary stimulation.  CD4+ T cells purified from spleen were ConA-stimulated, expanded with IL-2 
and restimulated with ConA in the presence of zVAD.  Western blot showed PKCθ, p65 and AKT hyper-
phosphorylation as well as increased CARMA1, BCL10 and TRAF6 protein levels in p21-/- T cells after 
secondary TCR challenge.  β-actin was used as loading control. In all cases, representative data are shown 
(n = 5). 
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FIGURE 7 |  p21 does not influence activation of naïve CD4+ T cells.  CD4+ T cells purified from spleen 
were ConA stimulated for indicated times in the presence of zVAD.  A. Western blot showed similar 
phosphorylation and protein levels (as in Fig. 6) in both WT and p21-/- naïve CD4+ T cells.  β-actin was used 
as a loading control.  Representative data are shown (n = 5). 
p21 localizes in cytoplasm and nucleus  of CD4+ T cells after repeated stimulation 
Lack of p21 led to increased phosphorylation and higher protein levels after T cell 
restimulation.  p21 has various roles, depending on its localization in cytoplasm or the 
nucleus 75.  Schepers et al. found that, in monocytic cells, p21 expression in cytoplasm 
or nucleus is related to the PKC-dependent pathway 76.  To analyze p21 localization 
during T cell activation in CD4+ T cells after secondary stimulation, we transfected CD4+ 
T cells from WT mice with a plasmid containing p21, and restimulated them with ConA at 
indicated times.  Confocal microscopy analysis showed that p21 localized to the 
cytoplasm and nucleus of memory T cells (Figure 8). 
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FIGURE 8 |  p21 localizes in cytoplasm and nucleus of memory T cells after restimulation.  YFP 
plasmids containing p21 were transfected into T cells using Nucleofector Kits for Mouse T Cells.  Cells were 
plated on poly-L-lysine-coated chamber slides.  At 4-24 h post-transfection, cells were restimulated with 
ConA and mounted with DAPI (blue)-containing mounting medium for confocal microscopy.  Representative 
results are shown (n = 2). 
p21 is a negative regulator of IFN-γ  production in TCR-dependent restimulated 
CD4+ T cells 
We found that p21 is a negative regulator of memory T cell activation.  As T cell 
stimulation with ConA produces IFN-γ 77, we determined the outcome of activation.  
CD4+ T cells were restimulated with ConA for 24 h and stained for IFN-γ production.  
Flow cytometry analysis showed increased IFN-γ in CD44hiCD62Lhi effector (Figure 9A) 
and CD44hiCD62Llo memory (Figure 9B) p21-/- CD4+ T cells compared to WT.  Further 
analysis of cytometry data indicated slightly more memory CD4+ T cells in the absence 
of p21, although the percentage of effector T cells was similar in both CD4+ cell 
populations (Figure 9C).  p21 thus regulates IFN-γ production in restimulated T cells.  
These data show that higher activation levels parallel higher IFN-γ production. 
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FIGURE 9 |  Lack of p21 increases IFN-γ  production in memory CD4+ T cells after TCR-dependent 
stimulation.  Spleen CD4+ T cells were ConA stimulated for 24 h, expanded in IL-2 for 6 days, and 
restimulated with ConA for 24 h.  Control cells were restimulated with IL-2.  A. Frequency of IFN-γ-producing 
CD62LhiCD44hi effector cells and B. CD62LloCD44hi memory WT and p21-/- CD4+ T cells.  C. Flow cytometry 
analysis showed the frequency of CD62L/CD44 and CD4+ T cells after 24 h ConA stimulation.  Cells were 
stained for CD4 expression and intracellular IFN-γ and analyzed by flow cytometry.  A representative 
experiment is shown (n = 3). 
As we found p21 influence in T cell activation and IFN-γ production following secondary 
stimulation, and that p21 does not affect CD4+ T cell activation after primary stimulation, 
we evaluated IFN-γ production in these cells.  Naïve CD4+ T cells were exposed to IL-12 
and IL-18.  Flow cytometry data showed that the frequency of IFN-γ-producing cells was 
similar (Figure 10A).  Populations of naïve and effector CD4+ T cells were similar 
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(Figure 10B, right) and nearly 95% were CD44hiCD62Lhi effector T cells (Figure 10B, 
left).  CD62LhiCD44hi effector T cells produced equivalent amounts of IFN-γ in p21-/- and 
WT naïve CD4+ T cells (Figure 10C). 
FIGURE 10 |  p21 does not affect IFN-γ  production after primary stimulation.  Purified spleen CD4+ 
T cells were stimulated with IL-12/IL-18 for 24 h.  IL-2-stimulated cells were used as control.  A. Frequency 
of IFN-γ-producing cells.  Cells were stained for CD4 expression and IFN-γ and analyzed by flow cytometry. 
B. Flow cytometry analysis showed the frequency of CD62L/CD44 and CD4+ T cells after 24 h stimulation 
with IL-12/IL-18.  C. Frequency of IFN-γ-producing CD62LhiCD44hi effector T cells.  Data show mean ± SEM 
(n = 2; ****p<0.0001). 
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p21 affects CD4+ T cell activation and IFN-γ  production following combined TCR-
dependent and -independent stimulation 
Using ConA, we showed that p21 regulates memory T cells.  We analyzed the effect of 
p21 on CD4+ T cell activation after ConA+IL-12/IL-18 restimulation.  Results showed 
increased phosphorylation and higher protein levels in cells from p21-/- mice (Figure 11). 
 
 
 
 
 
 
 
 
 
FIGURE 11 |  T cell stimulation by a combination of ConA + IL-12/IL-18 led to increased expression of 
proteins involved in the T cell activation pathway.  CD4+ T cells purified from WT and p21-/- spleen were 
stimulated with ConA, expanded with IL-2 and restimulated with ConA + IL-12/IL-18 in the presence of 
zVAD.  Immunoblot analysis showed levels of proteins involved in T cell activation. β-actin was used as 
loading control.  A representative experiment is shown (n = 2). 
We observed increased T cell activation in p21-deficient memory T cells after ConA + 
IL-12/IL-18 stimulation.  To test for IFN-γ production in these cells, WT and p21-/- CD4+ 
T cells were restimulated with ConA + IL-12/IL-18 for 24 h.  Flow cytometry data showed 
that absence of p21 led to enhanced IFN-γ production in CD44hiCD62Lhi effector 
(Figure 12A) and CD44hiCD62Llo memory (Figure 12B) CD4+ T cells.  In addition, we 
detected a mild differences in memory CD4+ T cells (Figure 12C). 
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FIGURE 12 |  Absence of p21 enhanced IFN-γ  production in CD4+ T cells rechallenged with a 
combination of TCR-dependent and -independent stimuli.  Mouse spleen CD4+ T cells were ConA 
stimulated for 24 h, expanded in IL-2 for 6 days, and restimulated with ConA + IL-12/IL-18 for 24 h.  Control 
cells were restimulated with IL-2.  A. Frequency of IFN-γ-producing CD62LhiCD44hi effector and B.  
CD62LloCD44hi memory WT and p21-/- CD4+ T cells.  C. Frequency of CD62L/CD44 and CD4+ T cells after 
24 h. Cells were stained for CD4 expression and intracellular IFN-γ and analyzed by flow cytometry.  A 
representative experiment is shown (n = 3). 
p21 downregulation led to increased phosphorylation and levels of proteins 
involved in T cell activation pathways 
Using p21-/- T cells, we showed that p21 suppresses memory T cell activation.  To 
understand and clarify this unreported p21 function, we examined the effect of induced 
reduction of p21 expression after primary T cell activation.  We designed and 
synthesized siRNA for p21 underexpression.  A scrambled sequence was used as 
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control.  CD4+ T cells from WT mice were ConA stimulated and expanded in IL-2 for 5 
days.  For transfection, we used an Amaxa kit (Figure 13A).  Calibration experiments to 
determine the concentration needed to underexpress p21 indicated that 3 µM siRNA 
was the optimal concentration.  Data showed p21 reduction at almost all time points, 
which led to ERK1/2, AKT, PKCθ and p65 hyper-phosphorylation and increased 
CARMA1 levels in the transfected T cells (Figure 13B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 13 |  p21 underexpression using siRNA led to increased levels of proteins involved in T cell 
activation pathways.  A.  CD4+ T cells purified from WT mouse spleen were ConA stimulated and 
expanded with IL-2 for 5 days, followed by transfection using an Amaxa kit. At  4-24 h post-transfection, cells 
were restimulated with ConA in the presence of zVAD.  B. Western blot analysis after secondary stimulation 
and transfection.  β-actin was used as loading control. Data show a representative experiment (n = 4). 
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We lowered p21 expression using an Amaxa kit and observed its influence on T cell 
activation pathways.  To improve transfection in a more efficient, less aggressive system 
at lower RNA concentration, we used gold nanoparticles (AuNP) for delivery.  siRNA 
were conjugated to AuNP and used for transfection at 5 days post-IL-2 expansion.  The 
Amaxa kit was used as a control (Figure 14A).  Transfection efficiency was evaluated by 
flow cytometry analysis, which show an adequate rate (Figure 14B). 
 
FIGURE 14 |  CD4* T cell transfection by siRNA conjugated to gold nanoparticles.  A. CD4+ T cells 
purified from WT mouse spleen were ConA stimulated and expanded with IL-2 for days, followed by 
transfection using AuNP or the Amaxa kit as control.  At 4-24 h post-transfection, cells were restimulated 
with ConA in the presence of zVAD.  B. Transfection efficiency analysis by flow cytometry at 24 h post-
transfection. Representative data are shown (n = 5). 
CD4+ T cells were transfected with 180 nM siRNA conjugated to AuNP as well as siRNA 
without AuNP (used with an Amaxa kit).  With AuNP, we observed p21 underexpression 
as early as 1 h after T cell restimulation.  The data showed an increase in p-ERK1/2, 
p-AKT, p-PKCθ, and p-P65 as well as CARMA1 and TRAF6 in T cells transfected with 
p21 siRNA at indicated times (Figure 15A), whereas after transfection at the same 
siRNA concentration by Amaxa kit, p21 was not notably reduced and we thus detected 
no effect on proteins involved in T cell activation signaling pathways (Figure 15B). 
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FIGURE 15 |  p21 underexpression using siRNA conjugated to AuNP increased expression of 
proteins involved in T cell activation pathways.  CD4+ T cells purified from WT mouse spleen were ConA 
stimulated and expanded with IL-2 for 5 days, followed by transfection using A. AuNP or B. an Amaxa kit as 
control. At 4-24 h post-transfection, cells were restimulated with ConA in the presence of zVAD.  The graph 
(bottom) shows relative density of p21 expression in cells transfected with AuNP.  Fiji software was used to 
quantify band density.  β-actin was used as loading control.  Data show a representative experiment (n = 4). 
To confirm the utility of this novel AuNP method for T cell transfection, we tested p21 
gene expression by RT-PCR after transfection and restimulation at indicated times. The 
results showed that p21 gene expression was reduced at 90 min post-restimulation. 
Scrambled siRNA was used as a control (Figure 16). 
 
 
Results 79 
 
 79 
 
 
 
 
 
 
 
FIGURE 16 |  Decreased p21 expression in T cells transfected by AuNP.  CD4+ T cells purified from WT 
mouse spleen were ConA stimulated and expanded with IL-2 for 5 days, followed by transfection using 
AuNP.  At 4-24 h post-transfection, cells were restimulated with ConA in the presence of zVAD.  RT-PCR 
analysis showed p21 expression at indicated time points.  β-actin was used as a housekeeping control. Data 
shown as mean ± SEM (n = 2). 
To analyze cell cytotoxicity in both transfection methods, we performed cell cycle 
analysis 24 h after the second stimulation (Figure 17).  Data indicated that tyransfection 
using AuNP yields less cell death (12.1%), which reached 30.5% with the Amaxa kit 
(electroporation); transfection with AuNP was thus less cytotoxic. 
 
 
 
 
 
 
 
FIGURE 17 |  Use of gold nanoparticles to transfect CD4+ T cells results in less cytotoxicity. PI staining 
and cell cycle analysis showed less cell death in AuNP-transfected T cells.  Data show a representative 
experiment (n = 5). 
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Using siRNA, we found hyperactivation of memory T cells following p21 reduction.  We 
therefore tested whether cytokine production is also influenced by p21 underexpression.  
RT-PCR results for IFN-γ and IL-10 gene expression showed increased IFN-γ production 
after transfection with p21 siRNA conjugated to AuNP, at indicated times post-
restimulation with ConA (Figure 18A); p21 underexpression did not affect IL-10 
production (Figure 18B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 18 |  Increased IFN-γ  production using p21 siRNA.  CD4+ T cells purified from WT mouse spleen 
were ConA stimulated and expanded with IL-2 for 5 days, followed by transfection using AuNP. At 4-24 h 
post-transfection, cells were restimulated with ConA in the presence of zVAD.  RT-PCR analysis showing A. 
IFN-γ and B. IL-10 expression.  β-actin was used as a housekeeping control.  Data show mean ± SEM (n = 
2). 
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p21 overexpression led to decreased phosphorylation and levels of proteins 
involved in T cell activation pathways 
We used in vitro stimulation studies to verify the role of transgenic p21 as an attenuator 
of T cell activation, in B6 and B6 p21 tg CD4+ T cells.  Western blot analysis showed 
high expression of transgenic p21 at 30 min post-restimulation.  The main effects were 
evident at this time, including lower phosphorylation of PKCθ, p65, AKT and ERK1/2 and 
reduced CARMA1 protein levels (Figure 19).  
 
 
 
 
 
 
 
 
 
 
FIGURE 19 |  p21 overexpression reduces activity of elements involved in T cell activation pathways 
after secondary stimulation.  CD4+ T cells purified from WT and p21tg mouse spleen were ConA 
stimulated, expanded with IL-2 and restimulated with ConA in the presence of zVAD.  Western blot showed 
less phosphorylation of p65, ERK1/2, AKT and PKCθ as well as a decrease in CARMA1 and BCL10 protein 
levels in p21 tg T cells after secondary TCR challenge.  β-actin was used as loading control.  Representative 
data are shown (n = 2). 
Upregulation of p21 gene expression using a plasmid reduced phosphorylation 
and expression of proteins involved in T cell activation pathways 
Use of transgenic p21 slightly reduced phosphorylation and activation of proteins 
involved in memory-like CD4+ T cells.  To clarify this finding, we considered it essential 
to examine the effect of induced enhancement of p21 expression after primary T cell 
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activation; we therefore cloned p21 in several plasmids (YFPn, YFPc and CFPn).  CD4+ 
T cells from WT mice were ConA stimulated and expanded in IL-2 for 5 days, followed 
by transfection using the Amaxa kit with 4 µg YFPn + p21 and the YFPn empty vector.  
Transfection efficiency was confirmed by flow cytometry analysis.  Western blot analysis 
showed that enhanced p21 led to a decrease in elements involved in T cell activation 
pathways, including p-PKCθ, p-AKT, p-ERK1/2, CARMA1 and BCL10 (Figure 20). 
 
 
 
 
 
 
 
 
 
 
FIGURE 20 |  T cell transfection by the plasmid (YFPn + p21) led to decreased activity of proteins 
involved in T cell activation pathways.  CD4+ T cells purified from WT mouse spleen were ConA 
stimulated and expanded with IL-2 for 5 days, followed by transfection using the Amaxa kit.  At 4-24 h post-
transfection, cells were restimulated with ConA in the presence of zVAD.  Western blot after secondary TCR 
challenge showed decreased ERK1/2, AKT and PKCθ phosphorylation, as well as a notable decrease in 
CARMA1 and BCL10 levels compared to controls (empty vector).  β-actin was used as loading control. Data 
show a representative experiment (n = 2). 
Overall we found that p21 negatively regulates memory-like CD4+ T cell activation after 
TCR-dependent restimulation.  Lack of p21 affects T cell activation pathways, leading to 
increased ERK1/2, AKT, PKCθ, STAT4, and p65 phosphorylation, enhanced CARMA1, 
BCL10, MALT1 and TRAF6 protein levels, and NF-κB activation. 
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Chapter 2: A role for p21 in TCR-independent activation of memory-like 
CD4+ T cells 
We showed that p21 regulates memory CD4+ T cells and IFN-γ production via TCR-
dependent activation.  We were therefore interested in determining whether p21 is also 
involved in TCR-independent activation of memory T cells. 
Lack of p21 led to increased phosphorylation and expression of protein in CD4+ 
T cells after IL-12/IL-18 stimulation 
CD4+ T cells were stimulated with ConA, expanded with IL-2 and restimulated 
individually with IL-12 or IL-18 in the presence of IL-2.  The data indicated that T cell 
stimulation by IL-12 led to hyper-phosphorylation of PKCθ and p65, and increased 
protein levels of CARMA1 and TRAF6 (Figure 21A).  When we used IL-18, we found 
increased phosphorylation of ERK1/2, PKCθ and p65 and enhanced protein levels of 
CARMA1 and BCL10 (Figure 21B) in p21-/- T cells.  Although we predicted an increase in 
STAT4 phosphorylation after IL-12 stimulation, this effect was not observed. 
FIGURE 21 |  T cell stimulation by individual IL-12 or IL-18 led to phosphorylation and expression of 
proteins involved in T cell activation.  CD4+ T cells purified from spleen were ConA stimulated and 
expanded with IL-2, then restimulated with IL-12 or IL-18 in the presence of IL-2 and zVAD.  Western blot 
analysis showed increased levels of proteins involved in T cell activation after A. IL-12 + IL-2 and B. IL-18 + 
IL-2 stimulation. Equal loading was visualized by β-actin expression. A representative experiment is shown 
(n = 2). 
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Several studies using IL-12 with IL-18 synergy have shown effects on T cell activation 
and IFN-γ production.  T cells stimulated with IL-12/IL-18 with no TCR-dependent 
stimulator promote IFN-γ more notably than T cells challenged with anti-CD3 and 
IL-12/IL-18 78.  We thus evaluated the p21 effect using IL-12 + IL-18.  Immunoblot 
analysis revealed enhanced phosphorylation and expression of proteins in p21-/- CD4+ 
compared with WT T cells (Figure 22). 
 
 
 
 
 
 
 
 
 
 
FIGURE 22 |  T cell stimulation by IL12/IL-18 led to a TCR-independent increase in T cell activation. 
CD4+ T cells purified from WT and p21-/- spleen were ConA stimulated, expanded with IL-2 and restimulated 
with IL-12/IL-18 in the presence of zVAD.  Immunoblot analysis showed increased levels of proteins involved 
in T cell activation.  β-actin was used as a loading control.  A representative experiment is shown (n = 2). 
p21-deficient memory T cells showed more NF-κB activation after IL-12/IL-18 
restimulation 
As several studies indicated that use of IL-12/IL-18 synergizes IFN-γ production due to 
STAT4 and NF-κB activation 79, we tested whether p21   affects STAT4 and NF-κB 
activation after IL-12/IL-18 restimulation.  Western blot analysis showed more STAT4 
phosphorylation in p21-/- compared with WT mice (Figure 23A).  In an electrophoretic 
mobility shift assay (EMSA), we found NF-κB activation strikingly enhanced at 1 h post-
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restimulation (Figure 23B).  p21 thus regulates IFN-γ production and Th1 induction via 
NF-κB activation. 
 
FIGURE 23 |  Increased STAT4 phosphorylation and NF-κB activation in p21-/- memory-like CD4+ 
T cells.  CD4+ T cells from spleens were ConA stimulated for 24 h, expanded in IL-2 for 6 days, and 
restimulated with IL-12/IL-18 in the presence of IL-2 for 24 h.  (A) Western blot showed increased pSTAT4 in 
p21-/- cells at indicated times in whole cell lysates.  Results were normalized to β-actin.  (B) EMSA analysis 
of nuclear extracts showing NF-κB protein complexes binding the consensus DNA sequence. Data show a 
(n = 2). 
We also identified increased STAT4 and p65 phosphorylation in p21-deficient memory 
T cells stimulated with specific peptides presented by macrophages (Figure 24). 
 
 
 
 
 
 
 
 
FIGURE 24 |  Lack of p21 led to an increase in pSTAT4 and p65 in memory-like CD4+ T cells after 
repeated stimulation with TCR-specific peptides presented by macrophages.  CD4+ T cells from tg 5cc 
IAK and tg 5cc IAK p21-/- mouse spleens were incubated with peptide-presenting macrophages for 24 h, 
expanded in IL-2 for 6 days, and restimulated with peptide-presenting macrophages for the indicated times. 
Western blot showed increased p-p65 and P-STAT4 levels of proteins involved in T cell activation.  β-actin 
was used as loading control.  Representative data are shown (n = 2). 
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p21 regulates IFN-γ  production in memory-like CD4+ T cells after repeated in vitro 
stimulation with IL-12/IL-18 
 
IL-18 and IL-12 synergistically induce IFN-γ production by T and B cells 78.  We showed 
that p21 regulates T cell activation when restimulated by IL-12/IL18.  To evaluate 
whether this p21 function operates through IFN-γ production, we stimulated CD4+ T cells 
with ConA and expanded cells with IL-2, followed by restimulation with IL-12 alone or IL-
12/IL-18 in the presence of IL-2 for 24 h, after which we stained for IFN-γ production.  In 
cells stimulated with IL-12 alone, cytometry analysis showed low IFN-γ production, which 
was similar in p21-/- and WT memory-like CD4+ T cells.  When we used IL-12/IL-18, 
however, we detected increased IFN-γ in CD44hiCD62Lhi effector (Figure 25A) and 
CD44hiCD62Llo memory (Figure 25B) p21-/- CD4+ T cells compared with controls.  In 
addition, the frequency of the cells that produced IFN-γ was higher in the absence of p21 
(Figure 25C).  The overall data indicated that p21 regulates T cell activation and IFN-γ 
production after TCR-independent stimulation. 
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FIGURE 25 |  Lack of p21 increases IFN-γ  production in effector/memory CD4+ T cells after repeated in 
vitro stimulation.  CD4+ T cells from mouse spleens were ConA stimulated for 24 h, expanded in IL-2 for 6 
days, and restimulated with IL-12/IL-18 in the presence of IL-2 for 24 h.  Control cells were restimulated with 
IL-12 + IL-2 or IL-2 alone.  A. Frequency of IFN-γ-producing WT and p21-/- CD4+ T cells.  B. Frequency of 
IFN-γ-producing CD62LhiCD44hi effector and C. CD62LloCD44hi memory WT and p21-/- CD4+ T cells.  Cells 
were stained for CD4 expression and intracellular IFN-γ and analyzed by flow cytometry.  A representative 
experiment is shown (n = 2). 
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Lack of p21 does not influence effector/memory T cells after IL-4 stimulation 
IL-4 promotes Th2 induction in CD4+ T cells.  We studied whether p21 affects IL-4-
stimulated T cells.  Immunoblot analysis showed increased phosphorylation of PKCθ and 
p65 in p21-/- CD4+ T cells compared with controls (Figure 26A).   Cell cycle analysis was 
also carried out 24 h after restimulation (Figure 26B). 
 
FIGURE 26 |  p21 does not influence memory-like T cells restimulated by IL-4.  CD4+ T cells purified 
from spleen were ConA stimulated for 24 h, expanded in IL-2 for 6 days, and restimulated with IL-4 for 
indicated times in the presence of zVAD.  A. Western blot analysis showing levels of different proteins 
involved in T cell activation pathways.  B. Cell cycle analysis at 24 h after restimulation.  Representative data 
are shown (n = 2). 
p21 affects the T cell activation pathway upstream of PKCθ  and acts as a negative 
regulator of memory-like CD4+ T cells 
We addressed a role for p21 as a regulator of memory-like CD4+ T cells.  To determine 
the interaction site of p21 on the T cell activation pathway, we stimulated T cells with 
PMA/ionomycin.  Western blot analysis showed similar PKCθ, p65, ERK1/2 
phosphorylation and CARMA1 protein levels in p21-/- and WT CD4+ T cells post-
PMA/ionomycin restimulation in the presence of zVAD (Figure 27A).  The levels of 
proteins involved in early T cell activation effects, such as pLCK and pZAP70, were 
similar in both cell populations (Figure 27B).  pAKT (Figure 27A,C) and TRAF6 
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(Figure 27C) were nonetheless increased in p21-/- CD4+ T cells compared to WT.   The 
data showed that p21 affects the T cell activation pathway upstream of PKCθ. 
 
FIGURE 27 |  p21 regulates the T cell activation pathway upstream of PKCθ  upstream.  CD4+ T cells 
purified from spleen were ConA stimulated, expanded with IL-2 and restimulated in a TCR-independent 
manner with PMA/ionomycin in the presence of zVAD.  Western blot showed similar kinetics during 
secondary stimulation for proteins downstream of PKCθ (A) and proteins involved in early T cell activation 
effects (B), but increased AKT phosphorylation (A, C) and TRAF6 levels (C), upstream proteins in the T cell 
activation pathway. Graphs show relative density.  Fiji software was used to quantify band density.  β-actin 
was used as loading control.  A representative experiment is shown (n = 3). 
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p21 does not affect the T cell activation pathway at the PI3K level 
Using PMA and ionomycin, we demonstrated that p21 affects T cell activation pathways 
upstream of PKCθ.  As we detected high AKT phosphorylation levels in p21-/- cells, we 
tested whether p21 interacts with molecules in the PI3K pathway for its function.  Results 
after ConA (Figure 28A) and PMA/ionomycin (Figure 28B) restimulation showed no 
differences in p85, p110 and PTEN protein levels, although AKT phosphorylation was as 
observed before (Figure 28). 
FIGURE 28 |  p21 does not affect PI3K levels in T cell activation pathways.  CD4+ T cells purified from 
spleen were ConA stimulated, expanded in IL-2 and restimulated with ConA and PMA/ionomycin in the 
presence of zVAD.  Western blot shows similar kinetics during secondary stimulation with ConA (A) and 
PMA/ionomycin (B). Graphs show relative density.  Fiji software was used to quantify band density.   β-actin 
was used as loading control. A representative experiment is shown (n = 2). 
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Chapter 3: p21 controls mitochondrial ROS production in CD4+ 
T cells 
Several studies have shown the role of mitochondrial reactive oxygen species (mROS) 
in T cell activation.  mROS increases TCR-induced signal transduction and ROS 
production is enhanced in this process 80.  As our lab found that p21 regulates mROS in 
macrophages, we evaluated the role of p21 in mROS production in CD4+ T cells. 
 Lack of p21 does not influence mROS production in naïve CD4+ T cells 
Our results showed that p21 does not affect naïve T cell proliferation, activation or IFN-γ 
production.  As we predicted, mROS was not influenced by p21 in these cells.  Purified 
naïve CD4+ T cells were ConA stimulated at early time points and MitoSOX Red dye was 
used in the last 30 min to detect mROS production.  Flow cytometry analysis showed 
similar mROS production in both p21-/- and WT cells (Figure 29). 
 
 
 
 
 
 
FIGURE 29 |  Mitochondrial superoxide production is similar in WT and p21-/- T cells after primary 
stimulation.  Flow cytometry analysis of mROS production measured by MitoSOX Red fluorescence.  CD4+ 
T cells from WT and p21-/- mouse spleens were ConA stimulated for indicated times.  The graph shows 
mean MitoSox fluorescence.  Data are expressed as mean ± SEM (n = 2); ****p<0.0001, two-way ANOVA 
with Bonferroni correction. 
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p21 deficiency leads to enhanced mROS production in memory-like CD4+ T cells 
We found that p21 is a negative regulator of activation and IFN-γ production in memory-
like CD4+ T cells.  We thus proposed that these p21 functions are associated with mROS 
production.  CD4+ T cells were ConA stimulated, expanded in IL-2 and restimulated with 
ConA.  Using MitoSOX Red, we detected more mROS production in p21-/- memory-like 
CD4+ T cells compared to controls (Figure 30). 
 
 
 
 
 
 
 
 
 
 
FIGURE 30 |  mROS production is enhanced in p21-/- memory-like CD4+ T cells.  mROS production 
measured by MitoSOX Red fluorescence.  Spleen CD4+ T cells from WT and p21-/- mice were ConA 
stimulated for 24 h, expanded in IL-2 for 6 days and restimulated with ConA at indicated early times. 
Histograms (top) show representative staining.  Median fluorescence intensities were standardized to the 
unstimulated cells of each cell type.  Data shown as mean ± SEM (n = 3); *p<0.05; **p<0.001, two-way 
ANOVA with Bonferroni correction. 
p21 regulates mROS production in CD4+ T cells rechallenged with TCR-
independent IL-12/IL-18 
To test whether p21 influences mROS production after TCR-independent challenge, 
second stimulation was carried out using IL-12/IL-18.  Flow cytometry analysis of mROS 
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production was evaluated by MitoSOX Red fluorescence.  Results again showed 
increased mROS production in p21-/- compared with WT CD4+ T cells at indicated early 
time points post-IL-12/IL-18 restimulation (Figure 31). 
 
 
 
 
 
 
 
 
 
 
- 
FIGURE 31 |  Mitochondrial superoxide production is increased in memory-like CD4+ T cells in the 
absence of p21.  Flow cytometry analysis of mROS production measured by MitoSOX Red fluorescence. 
CD4+ T cells from WT and p21-/- mouse spleens were ConA stimulated for 24 h, expanded in IL-2 for 6 days, 
and restimulated with IL-12/IL-18 for indicated times. Histograms (top) show representative staining.  Median 
fluorescence intensities were normalized to the unstimulated cells of each genotype.  Data shown as mean ± 
SEM (n = 3); **p<0.01; ***p<0.001, two-way ANOVA with Bonferroni correction. 
p21 overexpression reduces mROS production in B6-p21tg memory-like CD4+ T 
cells 
As we found that p21 is a negative regulator of mROS in memory-like CD4+ T cells, we 
tested whether p21 overexpression affects mROS production.  B6 p21 tg CD4+ T cells 
were restimulated with ConA, and mROS production was measured in flow cytometry. 
ROS production was reduced slightly at 30 and 60 min after restimulation (Figure 32). 
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FIGURE 32 |  p21 overexpression decreases mitochondrial superoxide production in B6 p21 tg 
memory-like CD4+ T cells.  Flow cytometry analysis of mROS production measured by MitoSOX Red 
fluorescence.  CD4+ T cells from WT and p21 tg mouse spleens were ConA stimulated for 24 h, expanded in 
IL-2 for 6 days, and restimulated with ConA for indicated times.  Histograms (top) show representative 
staining. Median fluorescence intensities normalized to the unstimulated cells of each genotype. Data shown 
as mean ± SEM (n = 2); **p<0.01, two-way ANOVA with Bonferroni correction. 
p21 does not affect mROS production in memory-like CD4+ T cells restimulated 
with PMA/ionomycin 
Since p21 regulates T cell activation upstream of PKCθ and does not affect IFN-γ 
production after PMA/ionomycin restimulation, we analyzed whether p21 influences 
mROS production in memory-like CD4+ T cells after PMA/ionomycin restimulation.  The 
results showed equal levels of mROS production in WT and p21-/- cells (Figure 33), 
which confirmed the effect of p21 on T cell activation after PMA/ionomycin treatment. 
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FIGURE 33 |  p21 does not affect mROS production in memory-like CD4+ T cells restimulated by 
PMA/ionomycin.  Flow cytometry analysis of mROS production measured by MitoSOX Red fluorescence.  
CD4+ T cells from WT and p21-/- mouse spleens were ConA stimulated for 24 h, expanded in IL-2 for 6 days, 
and restimulated with PMA/ionomycin for indicated times. Graphs show MitoSox Red mean fluorescence.  
Data are expressed as mean ± SD (n = 2); ****p<0.0001, two-way ANOVA with Bonferroni correction. 
Inhibition of mROS production decreases IFN-γ  production in memory-like CD4+ 
T cells 
We found that p21 regulates ROS production in memory-like CD4+ T cells after TCR-
dependent and -independent restimulation.  To identify the role of mROS and its relation 
with p21 in IFN-γ production and T cell activation, we inhibited mROS before the second 
stimulation. Mitochondrial oxidative phosphorylation is the main origin of ROS, as 
electron leakage appears at complex I, II and III, changing oxygen to superoxide 81.  
Diphenyliodonium (DPI) is a competitive flavin-containing cofactor inhibitor and therefore 
inhibits NOX-dependent ROS production.  DPI at higher concentrations can also block 
mROS production 82,83. This inhibition occurs at complex I (NADH-quinone 
oxidoreductase) and complex II (succinyl dehydrogenase).  Results using DPI showed 
that the mROS production decreased; levels were similar in p21-/- and WT CD4+ T cells 
post-IL-12/IL-18 restimulation, which suggests that p21 affects mROS production via 
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complex I or complex II (Figure 34A).  p21-/- and WT CD4+ T cells treated with DPI 
produced very small amounts of IFN-γ (Figure 34B).  Results showed that mROS is a 
notable regulator of IFN-γ production after IL-12/IL-18 restimulation and that p21 
influences mROS complexes I and II. 
 
FIGURE 34 |  Treatment of CD4+ T cells with mROS inhibitor decreased IFN-γ  production.  WT and 
p21-/- CD4+ T cells incubated with DPI (mitochondrial complex I and II inhibitor).  A. DPI treatment decreased 
mROS at 60 min post-IL-12/IL-18 restimulation.  B. Reduced frequency of IFN-γ-producing CD4+ T cells 
after DPI treatment.  Histograms (left) show representative staining. The graph (right) shows mean ± SEM 
(n = 3); ***p<0.001; ****p<0.0001, two-way ANOVA with Bonferroni correction. 
mROS improves CD44hi effector/memory T cell accumulation 
Metabolism in mitochondria has a critical role in memory T cell differentiation 86.  To 
determine whether p21 influences effector/memory T cell generation via its effect on 
mROS production, we evaluated memory phenotype in WT and p21-/- CD4+ T cells by 
measuring CD44 expression post-IL-12/IL-18 restimulation.  The data showed that, in 
the absence of p21, accumulation of CD44hi effector/memory T cells and the percentage 
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of IFN-γ-producing CD44hi memory cells increased compared with WT cells (Figure 35).  
In addition to decreasing the capacity of these cells to produce IFN-γ (Figure 34B and 
Figure 35), DPI treatment greatly altered their CD44hi memory phenotype (Figure 35).  
These data showed that mROS promotes memory T cell differentiation, and that p21 
regulates memory T cell accumulation and activation by controlling mROS. 
 
FIGURE 35 |  mROS inhibition decreases CD44+ effector/memory T cell accumulation.  Mouse spleen 
CD4+ T cells were ConA stimulated for 24 h, expanded in IL-2 for 6 days, and restimulated with IL-12/IL-18 
alone or in the presence of indicated antioxidants for 24 h.  CD44 expression was determined by flow 
cytometry.  Representative zebra plots are shown (left).  The graph (right) shows mean ± SEM (n = 3); 
****p<0.0001, two-way ANOVA with Bonferroni correction. 
p21 regulates memory-like CD4+ T cell activation via mROS 
p21 is a negative regulator of memory-like CD4+ cells after repeated stimulation.  We 
found that p21 regulates mROS production post-TCR restimulation, and tested whether 
increased mROS in p21-/- cells influences T cell activation pathways.  Results showed 
increased PKCθ, p65, AKT, STAT and ERK phosphorylation as well as CARMA1 and 
TRAF6 protein levels after ConA (Figure 36A) or IL-12/IL-18 (Figure 36B) restimulation 
in p21-/- compared with WT memory-like CD4+ T cells.  After DPI treatment, 
phosphorylation and protein levels were reduced in p21-/- CD4+ T cells, which reverted to 
WT cell levels (Figure 36).  p21 protein levels were unaffected by DPI treatment 
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(Figure 36), which shows that p21 acts upstream of mROS.  These results indicated that 
p21 is an important regulator of mROS production during memory-like CD4+ T cell 
activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 36 |  mROS Inhibition reverses hyperactivation of elements involved in T cell activation 
pathways in p21-/- memory-like CD4+ T cells.  Mouse spleen CD4+ T cells were ConA stimulated for 24 h, 
expanded in IL-2, and restimulated either with ConA (A) or IL-12/IL-18 (B). alone or with DPI.  Western blot 
analysis shows phosphorylation and protein levels in whole cell extracts.  p21 expression was unaffected by 
DPI treatment.  Equal loading was normalized by β-actin expression. Representative data are shown (n = 2). 
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Chapter 4: p21 effects on T cell activation and IFN-γ  production in 
autoimmunity-prone effector/memory lpr CD4+ T cells 
 
C57BL/6-lpr p21-/- mice display severe lupus-like symptoms, leading to death.  The 
mechanism by which p21 affects disease severity might be related to its control of T cell 
activation and IFN-γ production.  Here examined the effects of p21 on autoimmunity-
prone effector/memory lpr CD4+ T cells. 
p21 does not reverse the apoptosis defect in B6/lpr T cells 
Although p21 might inhibit apoptosis by interacting with proapoptotic proteins or by 
promoting cell cycle arrest 59, several other studies propose that p21 can have 
proapoptotic functions in defined conditions in specific systems 87,88.  To determine the 
role of p21 as an apoptosis inducer in B6/lpr mice after T cell stimulation, we analyzed 
apoptosis induction in B6/lpr and p21-/-/lpr CD4+ T cells using annexin-V and PI double 
staining.  B6 mouse T cells were used as controls.  The annexin-V+PI- subset indicates 
apoptotic T cells and the annexin-V+PI+ population consists of post-apoptotic, dead T 
cells.  The results showed similar, deficient apoptosis for B6/lpr and p21-/-/lpr CD4+ T 
cells after repeated stimulation (Figure 37). I n addition, Western blot analysis after 
second stimulation indicated that p21 deficiency is not affected at the level of proteins 
involved in the apoptosis cascade, such as caspase 8, caspase 3, FAAD or PARP, in 
B6/lpr or p21-/-/lpr mice (Figure 38). These results exclude a role for p21 as a possible 
apoptosis inducer. 
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FIGURE 37 |  Lack of p21 does not reverse lpr CD4+ T cell apoptosis.  B6, B6/lpr and p21-/-/lpr mouse 
CD4+ T cells after primary ConA stimulation and expansion in IL-2, restimulated with ConA at indicated 
times.  Annexin-V and PI double staining showed similar apoptosis levels in B6/lpr and p21-/-/lpr T cells.  B6 
cells were used as control.  Representative histograms are shown (n = 3). 
 
 
 
 
 
 
 
FIGURE 38 |  p21 does not affect levels of proteins involved in the apoptosis cascade in FAS-deficient 
mice.  B6/lpr and p21-/-/lpr mouse CD4+ T cells after primary ConA stimulation and expansion in IL-2, 
restimulated with ConA at indicated times.  Western blot showed similar levels of several proteins involved in 
T cell apoptosis.  B6 and p21-/- T cells were used as controls.  β-actin was used as a loading control.  
Representative data are shown (n = 3). 
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p21 is a negative regulator of T cell activation in B6/lpr mice 
Several studies from our lab showed that lack of p21 in autoimmunity-prone mice leads 
to severe lupus-like disease and finally, to death 64.  These analyses suggested that p21 
does not influence apoptosis promoted by Fas/Fas ligand (FasL), and showed that p21 
affects and regulates proliferation of memory-like CD4+ T cells.  To show that p21 
controls autoreactive T cells, we used B6/lpr as well as p21-/-/lpr mice.  Immunoblot 
analysis of memory-like CD4+ T cells post-ConA restimulation showed increased 
ERK1/2, AKT, PKCθ and p65 phosphorylation and BCL10 and CRMA1 protein levels in 
p21-/-/lpr compared with B6/lpr cells (Figue 39). 
 
FIGURE 39 |  p21 regulates memory-like CD4+ T cell activation in B6lpr mice.  CD4+ T cells from B6/lpr 
and p21-/-/lpr mouse spleen were ConA stimulated for 24 h, expanded in IL-2 for 6 days, and restimulated 
with ConA for indicated times.  Western blot showed increased phosphorylation and protein levels in 
p21-/-/lpr T cells. Equal loading was confirmed by β-actin expression. Representative data are shown (n = 3). 
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Using EMSA analysis, we found enhanced NF-κB activation at different times in lpr p21-
deficient memory-like CD4+ T cells (Figure 40). 
 
 
 
 
FIGURE 40 |  Lack of p21 led to increased NF-κB activation in lpr memory-like CD4+ T cells.  EMSA 
analysis of nuclear extracts shows NF-κB protein complexes binding the consensus DNA sequence.  NFY 
was used as loading control.  Representative data are shown (n = 3). 
Lack of p21 increases IFN-γ  production in p21-/-/lpr T cells after repeated 
stimulation 
Our lab found that p21 overexpression reduced IFN-γ production in B6/lpr CD4+ T cells 
after repeated stimulation 6.  As we determined that p21 regulates effector/memory CD4+ 
T cell and NF-κB activation, we sought to confirm the role of p21 as a regulator of IFN-γ 
production.  After primary TCR stimulation and IL-2 expansion, we restimulated cells with 
IL-12/IL-18.  The results showed increases in IFN-γ production and in the frequency of 
IFN-γ-producing CD62LhiCD44hi effector (Figure 41A) and CD62LloCD44hi memory 
(Figure 41B) CD4+ T cells from p21-/-/lpr compared with B6/lpr mice.  These data show 
that p21 is a negative regulator of IFN-γ production in lpr effector/memory CD4+ T cells.  
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FIGURE 41 |  Increased IFN-γ-production in p21-/-/lpr effector/memory T cells.  CD4+ T cells from B6/lpr 
and p21-/-/lpr mouse spleen were ConA stimulated for 24 h, expanded in IL-2 for 6 days, and restimulated 
with IL-12/IL-18 in the presence of IL-2 for 24 h.  IL-2 alone was used as a control.  Flow cytometry analysis 
shows the frequency of IFN-γ-producing A. CD44hiCD62Lhi effector and B. CD44hiCD62Llo memory CD4+ 
T cells. Cells were stained for CD4 expression and intracellular IFN-γ and analyzed by flow cytometry.  A 
representative experiment is shown (n = 3). 
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Discussion 
Immune system homeostasis is a critical process by which the body establishes and 
maintains cell tolerance.  This function is achieved by balancing cell activation, growth 
and death.  Autoreactive or activated cells are excluded by apoptosis, which leads to 
homeostasis.  Previous studies from our lab, published and unpublished, determined 
that p21 is involved in a variety of activities and has important functions in both innate 
and adaptive immunity.  Although p21 inhibits the NF-κB activation pathway in 
macrophages, the mechanism by which it mediates these regulatory activities in T cells 
remains elusive.  Here we sought to define several mechanistic issues. 
Role of p21 in macrophage activation 
Several studies have identified a role for p21 in macrophage activation.  p21 is involved 
in regulation of the cell cycle and transcription, and also protects macrophages against 
apoptotic factors 72.  It is a negative regulator of macrophage activation 7,70, and acts by 
downmodulating NF-κB activation.  Lack of p21 leads to an increase in the expression of 
cytokines such as IL-1β and TNF-α, which are induced by LPS in macrophages.  This 
increase in cytokine levels leads to enhanced activation of p21-/- macrophages 7,70.  p21 
is a negative regulator the NF-κB activation pathway after a first LPS challenge 7, 
although p21 did not influence this activation in LPS tolerance, and similar NF-κB 
activation was found in p21-/- and WT macrophages after rechallenge.  A recent study in 
our laboratory nonetheless we showed that p21 regulates the balance between p65-p50 
and inhibitory p50-p50 dimers 8.  The interaction of B cell lymphoma 3-encoded protein 
(BCL3) with p50-p50 is an important pathway, and increases the p50-p50 inhibitory 
effect on NF-κB, as it stabilizes homodimer binding 75,89,90. Lack of BCL3 leads to 
increased p50-p50 ubiquitination and degradation 75.  We nevertheless found reduced 
p50-p50 ubiquitination in p21-/-macrophages (Figure 1), and established that p50-
p50:DNA binding affinity in p21-deficient macrophages is impaired, which results in 
decreased binding of p50-p50 but not of p65-p50.  p21-deficient macrophages thus 
show a higher frequency of DNA-bound p65-p50 than p50-50.  As p50 ubiquitination 
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occurs after its binding to DNA 75, we considered that p21 deficiency could reduce p50-
p50:DNA binding affinity, leading to decreased p50 ubiquitination. 
Decreased p50-p50 binding affinity can be related to p50 phosphorylation, a 
posttranslational modification associated with p50-p50 DNA-binding capacity 76.  We 
found decreased p50 phosphorylation in p21-/- macrophages at 15 min post-LPS 
rechallenge (Figure 1).  This finding shows that p21 modulates macrophage regulatory 
upstream events, which control p50 posttranslational modifications and regulate p50 
binding affinity to the NF-κB DNA-binding site. 
We found that p21 affects p50 ubiquitination in macrophages.  We thus studied whether 
p21 influences another element with a central role in innate immunity, TRAF6.  TRAF6 is 
an essential signaling molecule in innate and adaptive immunity, that regulates TLR 
signaling to NF-κB 31.  Several studies have addressed the role of TRAF6 ubiqutination 
in macrophages 89–91.  During TRAF6-induced NF-κB activation, TRAF6 is ubiquitinated 
by K63 ubiquitin-type linkages 92.  TRAF6 ubiqutination was reduced in p21-/- 
macrophages after LPS rechallenge (Figure 2). 
These results confirm and extend our previous studies, and further emphasize the 
importance of p21 function in macrophage activation, although further research is 
needed to determine how p21 is involved in ubiquitination.  Based on these p21 effects 
in macrophage activation, we studied the role of p21 in T cell activation and the 
mechanisms involved in its regulation. 
p21 is a negative regulator of memory-like CD4+ T cells after repeated stimulation 
Previous studies from our lab showed that p21 regulates T cell responses after repeated 
stimulation 3,73, but the mechanism underlying this effect was unknown.  Following 
secondary stimulation with TCR-dependent agents, p21-/- CD4+ T cells showed 
hyperphosphorylation of ERK1/2 and p38 at early times after rechallenge, which 
indicated T cell hyperactivation in the absence of p21 (Figure 3). 
p21 is important for T cell activation after recurrent TCR-specific and -nonspecific 
stimulation.  We therefore attempted to identify this effect in more physiological 
conditions.  TCR-specific peptides were presented by macrophages to CD4+ T cells.  
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After a second stimulation, we observed increased pERK1/2 and p-p38 in p21-deficient 
CD4+ T cells.  Further [3H] thymidine uptake analysis also showed more proliferation in 
p21-/- T cells (Figure 4).  Findings were similar after T cell activation with ConA, which 
suggests that p21 affects activation of memory-like CD4+ T cells after repeated 
stimulation. 
p21 does not affect naïve CD4+ T cell proliferation 4,5. Our data here indicated no p21 
effects on CD4+ T cells after primary stimulation, since we found similar phosphorylation 
of ERK1/2 in WT and in p21-/- naïve T cells (Figure 5). 
We identified hyperactivation of memory CD4+ T cells after a second stimulation in p21-
deficient mice, and tested whether p21 affects other molecules with important roles in 
the T cell activation pathway.  Analysis of memory-like CD4+ T cells after TCR 
restimulation showed more phosphorylation of AKT (PI3K pathway), PKCθ, p65 (NF-κB 
pathway), and an increase in CARMA1, BCL10 and TRAF6 protein levels was seen in 
p21-/- T cells as early as 15 min after secondary stimulation (Figure 6).  These data 
showed that p21 negatively regulates phosphorylation and protein levels in T cell 
activation.  After primary stimulation, however, similar phosphorylation and protein levels 
in WT and p21-deficient naïve CD4+ T cells were observed (Figure 7).  These findings 
established that p21 affects memory-like but not naïve CD4+ T cell activation by 
regulating phosphorylation and protein levels. 
p21 localization is important for several effects on T cell activation 
The subcellular localization of p21 influences its wide range of functions.  Nuclear p21 
promotes tumor suppressor signals, whereas in the cytoplasm p21 activates oncogenic 
pathways 93.  In primary colon cancers, loss of nuclear p21 is associated with upstream 
activation of activin/PI3K, but nuclear p21 is linked to TGFβ/MEK/ERK pathway 
activation 94.  p21 localization is thus a key question in T cell activation. 
We identified p21 localization after repeated challenge during T cell activation; p21 was 
found in the cytoplasm and nucleus of memory-like CD4+ T cells post-restimulation 
(Figure 8).  A cytoplasmic localization allows p21 to interact with and regulate various 
proteins involved in T cell activation signaling pathways; these include ERK, PKCθ, the 
CBM complex, TRAF6 and AKT.  Localization at both cell sites could explain the roles 
108 	
 
 108 
mediated by p21.  p21 was also observed in the mitochondria.  Mitochondria are 
necessary for formation of the procaspase 3-p21 complex, which suggests that the 
mitochondria are involved in cell death, by death induction or by suppression 60.  As 
mitochondria have an important role in p21 activation, the mitochondria-p21 interaction 
might require further analysis.  We will later discuss the role of p21 in mROS 
(mitochondrial reactive oxygen species) production. 
p21 is a negative regulator of IFN-γ  production in TCR-dependent restimulated 
CD4+ T cells 
Previous findings with tg p21 mice suggested that p21 is a negative regulator of 
IFN-γ production in T cells.  Here we tested whether p21 affects IFN-γ production in 
effector/memory CD4+ T cells.  IFN-γ is an important cytokine in innate and adaptive 
immunity.  This cytokine has a variety of properties such as antiviral, immunoregulatory, 
and anti-tumor functions.  IFN-γ is secreted by Th1, cytotoxic T cells (TC cells), and NK 
cells 95.  T cell stimulation with ConA produces IFN-γ 77.  We found enhanced IFN-γ 
production in effector and memory p21-/- CD4+ T cells after ConA-restimulation.   In the 
absence of p21, the memory CD4+ T cell population was larger, although the percentage 
of effector T cells was similar in CD4+ cells from p21-/- and WT mice (Figure 9).  These 
data indicated that p21 is a negative regulator of IFN-γ production in memory CD4+ T 
cells  
p21 does not influence CD4+ T cell activation following first stimulation, and we observed 
similar IFN-γ production in WT and p21-deficient CD4+ T cells after IL-12/IL-18 
stimulation.  Populations of naïve and effector CD4+ T cells were also similar (Figure 10).  
p21 therefore does not affect IFN-γ production after primary stimulation, which further   
confirms a lack of p21 effect on naïve T cells. 
 
p21 affects CD4+ T cell activation and IFN-γ  production following combined TCR-
dependent and -independent stimulation 
T cells stimulated with IL-12/IL-18, with no TCR-dependent stimulus, promote more IFN-
γ production than T cells challenged with anti-CD3 + IL-12/IL-18 78.  We therefore 
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analyzed the effects of p21 on memory-like CD4+ T cell activation after ConA + IL-12/IL-
18 restimulation.  Our results showed that lack of p21 led to increased phosphorylation 
and protein levels in p21-deficient effector/memory CD4+ T cells (Figure 11), although 
the effect was not as strong as seen in ConA-stimulated T cells.  We also checked IFN-γ 
production in these cells; data showed more IFN-γ production in p21-/- T cells (Figure 
12), which indicated that, in the absence of p21, hyperactivated effector/memory CD4+ T 
cells produced higher IFN-γ levels. 
p21 downregulation led to increased phosphorylation and protein levels involved 
in T cell activation pathways 
Using p21-/- T cells, we showed that p21 suppresses memory T cell activation.  To 
exclude the possibility that this p21 effect on T cell activation is not depend on an effect 
of lack of p21 on T cell maturation and or primary activation, we examined the effect of 
induced reduction of p21 expression before secondary T cell activation. 
We used siRNA to suppress p21 expression.  With a conventional electroporation 
method (Amaxa kit) for CD4+ T cell transfection, high siRNA concentrations (3 µM) were 
needed to reduce p21 expression.  Although these lower p21 levels led to hyper-
phosphorylation and to increased protein expression in transfected T cells (Figure 13), 
this method affected the p21 expression pattern and led to high cytotoxicity.  To 
overcome these limitations and mimic more physiological conditions, we transfected the 
cells using a novel gold nanoparticle method (AuNP).  Gold nanoparticles can be 
synthesized at low size dispersity 96, are easily modified with different molecules 97,98, 
and have low toxicity 99,100.  We transfected CD4+ T cells using siRNA conjugated to 
AuNP.  Transfection efficiency was acceptable for both systems (AuNP and Amaxa; 
Figure 14); with less cell death and lower cytotoxicity in AuNP-mediated transfection 
compared to the Amaxa method (Figure 17).  When using 180 nM siRNA conjugated to 
AuNP, we observed p21 downregulation as early as 1 h after T cell restimulation, which 
led to hyperphosphorylation and increased levels of proteins involved in T cell activation 
pathways (Figure 15A).  After transfection using the Amaxa kit at the same siRNA 
concentration, p21 was not markedly reduced and we detected no effect on proteins 
involved in T cell activation (Figure 15B).  These data suggest that the p21 effects on 
memory-like CD4+ T cells are not only a result of p21 knockout, but are also observed 
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following p21 reduction after T cell activation.  Transfection by AuNP and p21 reduction 
was confirmed using RT-PCR, which also found downregulation of the p21 gene as early 
as 1 h after T cell restimulation (Figure 16). 
Using siRNA, we identified the role of p21 in memory-like CD4+ cells after T cell 
activation.  We therefore evaluated whether cytokine production is also influenced by 
p21 reduction.  Data showed increased IFN-γ production by cells with reduced p21 
through AuNP-conjugated siRNA, but p21 downregulation did not affect IL-10 production 
(Figure 18).  These findings confirmed our previous data regarding the role of p21 as a 
negative regulator of IFN-γ production. 
Our findings showed that use of AuNP as delivery systems for oligonucleotides in T cells 
is an improved method, since the system induces minimal death and leads to very early 
reduction of the target protein.  In addition, in the AuNP system, the siRNA concentration 
needed to reduce p21 is much lower than for the Amaxa kit.  These AuNP characteristics 
are critical for systems in which manipulation of a target protein must be rapid.  This is 
the case for activation of T cells, which occurs within the first hours after their 
stimulation. 
p21 overexpression reduces activation of memory-like CD4+ T cells in WT mice 
As p21 reduction increased T cell activation, we also used p21 transgenic mice to obtain 
further data relative to p21 regulatory effects on memory-like CD4+ T cells.  We found 
decreased phosphorylation and protein levels in transgenic CD4+ T cells up to 30 min 
post-restimulation, as well as higher levels of transgenic p21 at this time (Figure 19).  
Transgenic p21 levels were subsequently reduced, an effect related to the LCK 
promoter, and the transgenic p21 influence was no longer clearly visible.  Transgenic 
p21 is therefore functional up to 30 min.  We previously showed that tg p21 reduced 
IFN-γ production, although it was unclear whether this depends on T cell activation or 
proliferation.  Here we found less T cell activation at early times after rechallenge, which 
implies a link to T cell activation. 
As this transgenic system and p21 expression depend on the LCK promoter, we 
analyzed p21 overexpression effects independently of tg p21.  We examined the effect 
of plasmid-induced enhancement of p21 expression after T cell activation, using a 
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plasmid to transfect CD4+ T cells before secondary stimulation.  The data showed a 
clear, prolonged reduction in phosphorylation and protein levels in control CD4+ T cells 
after restimulation (Figure 20).  These findings confirmed the role of p21 as a negative 
regulator of memory-like CD4+ T cells. 
p21 regulates memory-like CD4+ T cells after TCR-independent stimulation 
We showed that p21 is negative regulator of memory-like T cells via TCR-dependent 
restimulation.  To determine whether p21 affects memory-like CD4+ T cells in a TCR-
independent manner and to examine its relationship with IFN-γ production, we stimulated 
IL-2-expanded CD4+ T cells with IL-12 or IL-18.  After engagement of IL-12, STAT4 is 
phosphorylated, which regulates IFN-γ production.  IL-18 directs T cell activation through 
the MAPK and NF-κB pathways, stabilizes IFN-γ mRNA, and leads to enhanced IFN-γ 
production 27.  We found increased phosphorylation and higher protein levels after IL-12 
or IL-18 restimulation in the absence of p21.  pSTAT4, pERK and BCL10 levels were not 
enhanced after IL-12 challenge, however, nor did we find increased pAKT or TRAF6 
after IL-18 restimulation (Figure 21).  Although p21 regulates T cell activation after IL-12 
restimulation, it appears that p21 has a greater effect on IL-18-rechallenged CD4+ T cell 
activation, and that early p21 expression is detected after IL-18 restimulation.  
Nonetheless, neither of these cytokines affected IFN-γ production in effector/memory T 
cells. 
We thus used IL-12/IL-18 to further analyze the role of p21 in T cell activation.  The 
synergy between IL-12 and IL-18 involves many transcription factors, which bind to 
specific DNA sequences in the gene that encodes the IFN-γ promoter 28. CD4+ T cell 
restimulation by IL-12/IL18 led to increased phosphorylation and protein levels in p21-/- 
CD4+ cells (Figure 22).  In addition, we found increased p-STAT4 in p21-deficient T cells, 
and EMSA analysis showed greater NF-κB activation (Figure 23).  This sequence of 
events demonstrates that p21 also regulates CD4+ T cell activation after TCR-
independent rechallenge.  Further analysis of CD4+ T cells restimulated with strong 
peptides presented by macrophages gave similar results (STAT4 and p65 hyper-
phosphorylation) in p21-deficient cells (Figure 24), which confirmed our previous 
findings. 
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As stated above, the use of IL-12/IL-18 synergizes IFN-γ production as well as 
hyperactivation of NF-κB and STAT4 in p21-/- T cells.  We evaluated whether p21 affects 
IFN-γ production after IL-12/IL-18 restimulation.  IL-12 alone did not induce T cells to 
produce IFN-γ, which was similar in both effector and memory CD4+ T cells.  After IL-18 
addition, IFN-γ production was synergized and we observed that, in the absence of p21, 
this production was enhanced in effector and memory CD4+ T cells.  The frequency of 
IFN-γ-producing cells was also greater in the p21-deficient CD4+ T cell population 
(Figure 25).  These findings show that p21 regulates IFN-γ production after repeated 
TCR-independent restimulation, which could be an outcome of T cell hyperactivation. 
 
The p21 effects are upstream of PKCθ  in T cell activation 
p21 is a negative regulator of memory-like T cell activation via TCR-dependent and 
-independent stimulation. We analyzed the p21 interaction site in T cell activation 
pathways, using PMA/ionomycin for secondary stimulation. PMA enhances PKC 
activation independently of the TCR.  In addition to activating Ca2+/calmodulin-
independent signaling pathways, ionomycin induces hydrolysis of phosphoinositides and 
PKC activation in T cells 101. We showed equivalent phosphorylation and protein levels in 
p21-deficient and WT CD4+ T cells post-PMA/ionomycin restimulation.  pAKT and 
TRAF6 were nonetheless increased in p21-/- CD4+ T cells (Figure 27).  Overall, these 
data show that p21 affects the T cell activation pathway upstream of PKCθ. 
p21 does not affect the PI3K pathway 
As we found more AKT phosphorylation using PMA/ionomycin, we tested whether p21 
interacts with molecules in the PI3K pathway.  The PI3K signaling pathway regulates 
numerous processes in normal cells such as growth, proliferation, survival, motility, and 
metabolism 24.  Activated AKT controls several substrates important for cell survival, cell 
cycle and cell growth 25.  Our data from CD4+ T cells restimulated with ConA or 
PMA/ionomycin indicated no differences in protein levels involved in the PI3K pathway, 
such as p85, p110α and PTEN (Figure 28).  AKT hyperphosphorylation was nonetheless 
detected as before, possibly related to other pathways. 
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p21 controls mitochondrial ROS production in CD4+ T cells 
Mitochondria are part of the signaling complex at the immunological synapse (IS), and 
their localization near the IS is necessary for Th cell activation 47. mROS increases TCR-
induced signal transduction and ROS production is enhanced in this process 80, and 
mitochondria are needed for antigen-specific T cell activation through ROS signaling 102.  
p21 also was found in mitochondria, which suggested mitochondria involvement in cell 
death 60.  Unpublished data from our laboratory indicate that p21 regulates mROS in the 
macrophages (not shown).  We thus analyzed the role of p21 in mROS production in 
T cells. 
Naïve CD4+ T cells after primary TCR stimulation showed similar mROS production in 
WT and p21-/- T cells (Figure 29).  As predicted, p21 did not influence mROS in these 
cells.  These findings, combined with results for proliferation, activation and 
IFN-γ production, confirmed that p21 does not regulate naïve CD4+ T cells. 
As p21 is a negative regulator of effector/memory CD4+ T cell activation and IFN-γ 
production, we proposed that these p21 functions could be associated with mROS 
production. p21-deficient effector/memory T cells showed enhanced mROS production 
(Figure 30).  This effect also was shown in T cells rechallenged with IL-12/IL-18 in a 
TCR-independent stimulation, where we detected increased mROS production in p21-
deficient cells (Figure 31).  The role of p21 in TCR-dependent and -independent 
stimulation is linked to mROS production.  These p21 effects were further confirmed by 
p21 overexpression; in p21 transgenic mice, we found a modest decrease in mROS 
production in B6-p21tg CD4+ T cells (Figure 32). 
Analysis showed that the use of PMA/ionomycin for secondary stimulation of T cells led 
to similar mROS production in WT and p21-/- effector/memory CD4+ T cells (Figure 33), 
which confirmed our finding that p21 does not influence T cells after PMA/ionomycin 
restimulation.  We therefore propose a sequence of effects in which p21 is a negative 
regulator of mROS production and controls T cell activation through or upstream of 
mitochondria. 
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p21 regulates effector/memory CD4+ T cell activation via mROS 
Our findings suggested that p21 is a negative regulator of mROS production in 
effector/memory CD4+ T cells during both TCR-dependent (ConA) and -independent 
(IL-12/IL-18) stimulation (Figures 30 and 31).  This was confirmed using DPI, an inhibitor 
of mitochondrial complexes I and II.  We found, that p21-/- and WT CD4+ T cells 
produced very little IFN-γ showing that mROS is necessary for IFN-γ production in 
effector/memory T cells (Figure 34).  Mitochondrial metabolism has an important role in 
memory T cell differentiation 84.  We therefore evaluated whether p21 affects 
effector/memory T cell generation, via its impact on mROS production.  Analysis of 
cytometry data showed accumulation of CD44hi effector/memory T cells, and use of DPI 
altered their CD44hi memory phenotype (Figure 35).  These data indicate that mROS can 
promote memory T cell differentiation, and that p21 regulates memory T cell 
accumulation and activation by controlling mitochondrial ROS.  In confirmation of these 
results, phosphorylation and levels of proteins involved in T cell activation pathways 
were lower in p21-/- effector/memory CD4+ T cells after DPI treatment, and reversed to 
the levels seen in WT cells.  p21 levels were not influenced by DPI treatment (Figure 
36), which indicates that p21 acts upstream of mROS. 
These experiments determined that p21 is a negative regulator of mROS production in 
TCR-dependent and cytokine-induced reactivation, which controls certain components of 
the T cell activation pathway and IFN-γ production (Scheme 11). 
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SCHEME 11 |  p21 regulates effector/memory CD4+ T cell activation via mROS. p21 regulates TCR-
dependent and -independent through its influence on mROS. Phosphorylation and levels of proteins 
involved in T cell activation pathways were lower in p21-/- effector/memory CD4+ T cells after DPI (mROS 
inhibitor) treatment, and reversed to the levels seen in WT cells, as well as p21-/- and WT CD4+ T cells 
produced very little IFN-γ. These data identified that p21 regulates T cell activation through mROS. 
p21 suppresses IFN-γ  production and lupus-like autoimmunity 
p21 knockout mice develop normally and their cells progress through the cell cycle with 
no evident abnormalities 3.  p21-/- mice on the C57BL/6 (B6) background show mild 
autoimmune manifestations 5, and p21 was proposed as a suppressor of autoimmunity.  
In autoimmune male BXSB mice, lack of p21 leads to decreased disease 103.  Apoptosis 
signal deficiency in Fas-negative (LPR) mice causes lupus-like autoimmune disease and 
lymphoaccumulation. In these mice, effector/memory T cells hyperproliferate and 
hyperactivate, and produce high IFN-γ levels 104.  p21 thus has an autoimmune 
suppressor function. 
Despite these effects in Fas-deficient mice, we found that p21 does not reverse the 
apoptosis defect in these lpr cells.  Several studies indicated a role for p21 as an 
apoptosis inhibitor 58 and that it has pro-apoptotic functions 85,86.  We tested whether p21 
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affects the apoptosis defect in B6/lpr CD4+ T cells, and found similarly deficient 
apoptosis in both B6/lpr and p21-/-/lpr CD4+ T cells (Figure 37).  The levels of proteins 
involved in the apoptosis cascade were similar in both CD4+ T cell types (Figure 38).  As 
we showed that p21 does not reverse apoptosis defects in lpr mice, we evaluated 
whether p21 affects T cell activation.  Using B6/lpr tg p21 mice, our laboratory previously 
demonstrated that p21 negatively regulates T cell activation and IFN-γ, and reduces 
autoimmunity 6. To verify the p21 autoimmunity suppression effect in more physiological 
conditions and determine how this effect is exerted, we used p21-/-/lpr mice, which 
manifest higher lupus-like disease levels and death.  In accordance with the role of p21 
in T cell activation in p21-/- mice, we observed increased PKCθ, p65, and ERK1/2 
phosphorylation and BCL10 and CRMA1 protein levels in p21-/-/lpr compared with B6/lpr 
mice; we also found enhanced NF-κB activation post-restimulation (Figure 39).  In 
addition, we detected significantly enhanced IFN-γ production in p21-/-/lpr 
effector/memory CD4+ T cells (Figure 40). Thus, lack of p21 in B6/lpr mice led to 
increased effector/memory T cell activation, which gives rise to NF-κB hyperactivation 
and IFN-γ production.  Our findings regarding the role of p21 in autoimmune-prone mice 
are summarized in Scheme 12. 
 
 
 
 
 
 
 
SCHEME 12 |  p21 regulates autoreactive CD4+ T cell activation and IFN-γ  production.  Lpr mice 
deficient in Fas (CD95) show defective AICD (activation-induced cell death) and develop lymphadenopathy 
and lupus-like autoimmune disease.  In p21-/-/lpr mice, lack of p21 leads to increased activation and 
accumulation of memory T cells, and to NF-κB hyperactivation; IFN-γ levels are also higher.  These 
manifestations lead to severe glomerulonephritis and death in these mice.  p21 overexpression suppresses 
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B6/lpr double-negative T cell lymphadenopathy, and reduced effector/memory T cell proliferation and 
autoimmune symptoms. 
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CONCLUSIONS 
 
1. p21 negatively regulates effector/memory (memory-like) CD4+ T cell activation 
after TCR-dependent restimulation.  Lack of p21 affects T cell activation 
pathways, leading to increased phosphorylation of PKCθ, AKT, p65, STAT4, and 
ERK1/2, as well as protein levels of CARMA1, BCL10, MALT1, and TRAF6, and 
activation of NF-κB. 
2. p21 suppresses IFN-γ production in memory-like CD4+ T cells after repeated 
TCR-dependent stimulation.  Lack of p21 leads to enhanced IFN-γ production in 
p21-/- compared to WT cells. 
 
3. p21 is a negative regulator of memory-like CD4+ T cell activation and IFN-γ 
production  after TCR-independent restimulation. 
 
4. p21 is a negative regulator of mROS production in memory-like CD4+ T cells, 
after both TCR-dependent and -independent stimulation.  p21 thus controls 
mROS production and regulates T cell activity markers, leading to NF-κB 
hyperactivity and IFN-γ production, as well as memory-like CD4+ T cell 
generation. 
 
5. p21 regulates autoimmunity-prone memory-like lpr CD4+ T cells, and p21 
deficiency leads to NF-κB hyperactivation and increased IFN-γ production. 
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CONCLUSIONES 
 
1. p21 regula negativamente la activación de células T CD4+ de tipo memoria 
efectoras / memoria después de la reestimulación TCR-dependiente. La falta de 
p21 afecta a las vías de activación de las células T, dando lugar a una mayor 
fosforilación de PKCθ, AKT, p65, STAT4 y ERK1/2, como así también se ven 
afectados los niveles de proteína de CARMA1, BCL10, MALT1 y TRAF6 y la 
activación de NF-κB. 
2. p21 suprime la producción de IFN-γ en células T CD4+ de tipo memoria después 
de una estimulación repetida TCR-dependiente. La falta de p21 conduce a una 
producción incrementada de IFN-γ en p21-/- en comparación con células WT. 
3. p21 es un regulador negativo de la activación de células T CD4+ de tipo memoria 
y de la producción de IFN-γ después de una reestimulación TCR-independiente. 
4. p21 es un regulador negativo de la producción de especies reactivas de oxígeno 
mitocondriales (mROS) en células T CD4+ de tipo memoria, después de la 
estimulación tanto dependiente como dependiente de TCR. p21 controla así la 
producción de mROS y regula los marcadores de actividad de las células T, 
dando lugar a una hiperactividad de NF-κB y a la producción de IFN-γ, así como 
a la generación de células T CD4+ de tipo memoria. 
5. p21 regula las células T CD4+ con propensión a la autoinmunidad, de tipo 
memoria lpr. La deficiencia en p21 conlleva a una hiperactivación de NF-κB e 
incrementa la producción de IFN-γ. 
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